



## Cross-Network PBMC Processing Standard Operating Procedure

<b>Title:</b>	Cross-Network PBMC Processing SOP v8.0		
<b>Origination Date:</b>	01 April 2009	<b>Total Pages:</b>	39
<b>Effective Date:</b>	14 June 2026	<b>SOP Number:</b>	HANC-LAB-P0001 v8.0
<b>Written By:</b>	Cross-Network PBMC SOP Working Group	<b>Supersedes SOP Dated:</b>	19 August 2024

	Network	Name, Title	Signature	Date
<b>Approved By (Network):</b>	ACTG	Grace Aldrovandi MD ACTG Network Laboratory Principal Investigator	DocuSigned by: <i>Grace Aldrovandi</i> 6BE9A0BACDFE4FA...	DS <i>GA</i>
	HPTN	Estelle Piwowar-Manning, MT (ASCP) SI HPTN Network Laboratory Deputy Director	DocuSigned by: <i>Estelle Piwowar-Manning</i> 731B45B052A74D8...	DS <i>EPM</i>
	HVTN	Kathryn Dougherty, MT (ASCP) HVTN Associate Director Laboratory Quality and Compliance	Signed by: <i>Katy Dougherty</i> 7DCF2BEE1F91407...	Initial <i>KD</i>

<b>Revision History</b>	For a complete revision history, see Appendix I.
-------------------------	--

	Name, Title	Signature	Date
<b>Reviewed By (Laboratory):</b>			



# Cross-Network PBMC Processing Standard Operating Procedure

## Contents

1. PURPOSE .....	3
2. SCOPE .....	3
3. BACKGROUND .....	3
4. AUTHORITY AND RESPONSIBILITY .....	3
5. REPORTING RESULTS .....	3
6. SPECIMEN .....	5
7. EQUIPMENT .....	6
8. DISPOSABLES .....	7
9. PERSONAL PROTECTIVE EQUIPMENT .....	8
10. REAGENTS .....	8
11. REAGENT PREPARATION .....	10
12. PBMC PROCESSING INTRODUCTION AND GUIDELINES .....	13
13. CELL SEPARATION AND BLOOD DILUTION BY CELL SEPARATION TUBE WITH FRIT BARRIER (CSTFB) WITH PLASMA REPLACEMENT .....	14
14. CELL SEPARATION BY MANUAL DENSITY GRADIENT MEDIA OVERLAY OR UNDERLAY AND BLOOD DILUTION BY MANUAL DENSITY GRADIENT CELL SEPARATION WITH PLASMA REPLACEMENT .....	17
15. WASHING, COUNTING, RESUSPENSION, CONCENTRATION, AND OVERNIGHT CONTROLLED- RATE FREEZING .....	20
16. QUALITY CONTROL .....	23
17. PBMC STORAGE (INTERIM OR ON-SITE) .....	24
18. COMPLETING PROCESSING DOCUMENTS .....	25
19. DEFINITIONS AND ACRONYMS .....	25
20. REFERENCES .....	26
21. APPENDICES .....	26



## Cross-Network PBMC Processing Standard Operating Procedure

### 1. Purpose

- 1.1. This Standard Operating Procedure (SOP) describes procedures for the isolation and cryopreservation of Peripheral Blood Mononuclear Cells (PBMC) from whole blood.

### 2. Scope

- 2.1. This procedure is to be utilized for processing blood samples for the isolation, cryopreservation, and storage of PBMC samples.
- 2.2. Network protocol-specific instructions supersede those in this SOP.

### 3. Background

- 3.1. Freshly collected or cryopreserved PBMC are used for the evaluation of study objectives. These assays require PBMC that have been isolated and cryopreserved under strictly defined conditions that ensure optimal recovery, viability, and functionality. It is optimal for blood to be processed and frozen within 8 hours from the time of blood draw to maintain maximum function of the cells in immune- monitoring assays.

### 4. Authority and Responsibility

- 4.1. The Network Laboratory Center Directors/PIs (or designee(s)) have the authority to establish, review and update this procedure.
- 4.2. The HIV/AIDS Network Coordination (HANC) Office is responsible for the maintenance and control of SOP documentation.
- 4.3. The Processing Laboratory Director is responsible for the implementation of this HANC SOP and for ensuring that all appropriate personnel are trained.
- 4.4. All site and laboratory personnel involved in collecting, processing and/or management of PBMCs are responsible for reading and understanding this SOP prior to performing the procedures described.
- 4.5. The current HANC PBMC SOP must be used as written by all laboratories to obtain PBMCs for Network Protocols.

### 5. Reporting Results

- 5.1. Use of a PBMC Processing Worksheet and the Laboratory Data Management System (LDMS) is required for all networks to track key processing details including the timing of processing, calculations and documentation of problems that arise during processing.
  - 5.1.1. For HPTN and HVTN, the use of a protocol-specific PBMC Processing Worksheet in its entirety is required unless otherwise noted in the protocol Specimen Processing Laboratory Instructions (SPLI) or Laboratory Manual (LM). In the rare case that a protocol-specific PBMC worksheet is not required, the generic worksheet in Appendix A and at <http://www.hanc.info/labs/labresources/procedures/Pages/pbmcSop.aspx> may be used.
  - 5.1.2. For ACTG protocols, all components indicated in the ACTG PBMC Processing Worksheet in Appendix B must be captured.
- 5.2. Use of LDMS is Required to capture participant and processing information, generate unique identifiers, create cryovial labels, capture storage locations and generate shipping manifests.



## Cross-Network PBMC Processing Standard Operating Procedure

5.3. Key elements required for the tracking of PBMC processing include:

Key Elements Table	
Key elements for tracking PBMC processing	Where captured
Specimen Processing Laboratory	W L
Participant ID	W L
Visit Number	W L
Protocol	W L
LDMS Global Specimen ID	Auto-generated by LDMS
Processing Start Date/Time	W L
Processing Tech Initials (Tech)	W L
Counting Method (name of instrument or manual count)	W
Counting resuspension volume WDR (V)	W
Cell count average concentration (C)	W
Target number of cells per vial (N1)	W
Total cell number (T) = C x V	W L
Calculate the final CPS resuspension volume (V <sub>f</sub> )	W
Frozen Date and Time	W L
Comments and Protocol Deviations, including but not limited to: <ul style="list-style-type: none"> <li>All unexpected specimen conditions</li> <li>Clotted blood (number of tubes with clots, total number of tubes from the PTID batch, and processing details)</li> <li>Cell yield below expected range</li> <li>Processing anomalies</li> <li>Troubleshooting steps taken</li> <li>Note if Total Time &gt;8 hours</li> <li>Processing Time &gt;4 hours</li> </ul>	W
Collection Date/Time	W L
Reagents (Manufacturers, Lot Numbers and Expiration Dates for DMSO, FBS, WDR, CSTFB, density gradient media)	W
ACTG Only: FBS (Manufacturers, Lot Numbers, and Expiration Dates)	L
CPS (Volume of DMSO and FBS)	W
Sample tube type (HEP/ACD/EDTA/Other)	W L
Blood condition (e.g. SAT/HEM/CLT)	W L
Measured usable whole blood volume	W L
Cell Counts	W
Actual number of cells per vial (N2)	W L
Number of cryovials frozen	W L
Freezer storage information (LDMS Storage Module)	O L
Confirmation of visual QC of reagents (Tech)	O
Cell yield/mL of whole blood	W
Estimated CPS resuspension vol. (V1)	W
Confirmation of LDMS Label QC for content/barcodes (Tech)	W
Confirmation of cryovial transfer to storage box locations assigned by LDMS (Tech)	W
Date/time cryovials were transferred from controlled-rate freezing unit to storage box.	W
Final Reviews, Reviewers/Dates	W

W= Tracking on a PBMC worksheet is required

L = Entry/tracking in LDMS is required

O = Tracking on a worksheet or supplementary tracking material is optional



### 6. Specimen

6.1. Fresh anti-coagulated whole blood collected per the protocol requirements.

#### 6.2. Handling Conditions

6.2.1. Specimens should be stored at room temperature (15 to 25°C or up to 30°C, depending on climatic conditions) from the time of collection until delivery to the processing laboratory.

6.2.2. Specimens should be delivered to the processing laboratory as soon as possible (best practices would be within 30 minutes to 4 hours of collection) to allow the processing laboratory ample time to complete the cryopreservation procedures. Clinic should discuss specific requirements with processing laboratory before protocol enrollment.

6.2.3. Specimens should be processed by the processing laboratory as soon as possible upon receipt (best practices would be to begin processing within 30 minutes of receipt of sample):

- Processing Time (processing start time) is the time when the tube is first opened or placed in the centrifuge, whichever comes first.
- Frozen Time is defined as the time when:
  - The Agilent Technologies StrataCooler®, Nalgene® Mr. Frosty™ or Corning® CoolCell® is put into a freezer set at - 80°C. See SPLI/LPC/LM for acceptable temperature ranges to account for routine fluctuations in freezer temperatures.
  - The cooling program of the controlled-rate freezer, such as CryoMed®, has started.  
*Note:* Controlled-rate freezers are not allowed for HVTN samples.
- Total Time is calculated from Specimen Collection Time and Frozen Time; ideally, this is 8 hours or less, but all specimens should be processed regardless of the Total Time.
- Total Processing Time is calculated from the Processing Time and the Frozen Time; less than four hours is recommended and processing under 3 hours ideal.

6.2.4. Do not refrigerate or freeze whole blood. Do not place blood in direct contact with cold packs if you are using them during extreme heat conditions.

#### 6.3. Marginal Specimens

##### 6.3.1. Clotted specimens

6.3.1.1. All blood should be processed regardless of whether it is clotted, unless otherwise directed by protocol.

6.3.1.2. Remove the clot(s) and continue processing as usual.

6.3.1.3. Mark condition as CLT on the worksheet and in LDMS. Include details in the comments section of the processing worksheet.

##### 6.3.2. Hemolyzed specimens

6.3.2.1. Hemolysis may affect the quality of the PBMCs.

6.3.2.2. Process as usual.

6.3.2.3. Mark condition as HEM on the worksheet and in LDMS. Include details in the comments section of the processing worksheet.

##### 6.3.3. Low cell yield

6.3.3.1. If, after performing the cell counts, the cell yield is insufficient to meet the needs of the protocol, contact the clinic for possible specimen replacement. If the cell yield is  $\leq 0.4 \times 10^6$  cells/mL, contact the clinic for possible sample replacement and notify the network laboratory center (HVTN, HPTN) or protocol team (ACTG).

6.3.3.2. Capture troubleshooting or data verification steps taken in the comment section of the processing worksheet.

#### 6.4. Unacceptable Specimens

6.4.1. Unlabeled or mislabeled specimens will be rejected.

6.4.2. Follow network guidance for rejection of delayed specimens.

6.4.3. Leaking samples: Notify the clinic if any of the samples are leaking and determine whether the samples are



## Cross-Network PBMC Processing Standard Operating Procedure

usable. Sterility of the sample and safety of the laboratory personnel handling the samples are of particular importance.

### 7. Equipment

#### 7.1. Preparation & Processing

- 7.1.1. Class II biosafety cabinet (BSC) level 2 or higher
- 7.1.2. Centrifuge, low speed (capable of 200 to 1000 x g), with swinging bucket rotor, refrigerated preferred, ambient acceptable. Buckets with caps/lids are required.
- 7.1.3. Micropipettes, range 20, 200, 1000 $\mu$ L
- 7.1.4. Pipet-Aid (cordless preferred) for use with disposable, serological pipets
- 7.1.5. 2 to 8°C refrigerator
- 7.1.6. -20°C (or lower) freezer without automatic defrost (for FBS storage)
- 7.1.7. -80°C freezer (-65 to -95°C for ACTG, -70 to -95°C for HVTN and HPTN); for short-term PBMC storage.
- 7.1.8. 37 to 56°C water bath (for heat inactivating FBS, if necessary) (Note for HVTN: Not required for HVTN protocols; HVTN-approved FBS is provided to labs by network as heat inactivated).
- 7.1.9. Bucket or beaker for bleach or other disinfectant
- 7.1.10. Racks suitable for holding blood collection tubes, 15mL, and 50mL conical tubes upright during processing and transport steps
- 7.1.11. Cryovial rack to allow for one handed opening/closing of cryovials during aliquoting steps (Nunc specific rack preferred)

#### 7.2. LDMS required equipment. (Refer to LDMS website and network specific requirements for details).

- 7.2.1. Computer meeting specifications defined by Frontier Science for Web LDMS
- 7.2.2. Printer for LDMS generated labels
- 7.2.3. 2D barcode scanner
- 7.2.4. LN<sub>2</sub> compatible labels with 1x1 inch printable area
- 7.2.5. LN<sub>2</sub> compatible ink ribbon, printer specific, abrasion and chemical resistant

#### 7.3. Liquid Nitrogen (LN<sub>2</sub>) equipment (if required by network)

- 7.3.1. LN<sub>2</sub> storage tank ( $\leq$  -140°C)
- 7.3.2. IATA-approved LN<sub>2</sub> dry shipper

#### 7.4. Cell Counting:

**Note:** Counting methods may need network approval. Follow the applicable manufacturer's calibration procedures if using an automated cell counter.

- 7.4.1. Automated cell counter capable of enumerating viable cells (Beckman-Coulter Vi-Cell, Muse® or equivalent). HVTN does not typically approve this class of cell-counters for fresh samples.
- 7.4.2. Automated cell counter not capable of distinguishing viable cells (Coulter Counter, Abbott Cell-Dyn®, Sysmex® or equivalent).

**Note:** An automated cell counter not capable of identifying viable cells may be used to obtain a total cell count without distinguishing viable cells. However, specimens that are being prepared for the IQA PBMC Cryopreservation Proficiency Testing Program must include a viable cell count.

**Note for HVTN:** If automated counters are going to be used for protocol purposes, the network has a strong preference for this class of counters. Counting methods must be reviewed and pre-approved by the HVTN.

#### 7.4.3. Manual cell counting chamber (hemacytometer) and light-field microscope.

**Note:** If a manual cell counting chamber is used with trypan blue, viable cells must be enumerated and used for cell calculations. If crystal violet is used, total cell count can be used for cell calculations.



## Cross-Network PBMC Processing Standard Operating Procedure

### 7.5. Cryopreservation

**Note:** One of the following controlled-rate freezing units (CRFUs) may be used per the manufacturer's instructions; the Agilent Technologies StrataCooler® and Corning® CoolCell® are preferred.

**Note:** If manufacturer's instructions aren't followed, a validation study must be completed.

#### 7.5.1. Agilent Technologies StrataCooler® Cryo Preservation Module – 400005

7.5.1.1. StrataCooler® must be at 2 to 8°C before starting the cool down of the cryovials. Do not place cryovials in a StrataCooler® that is below an initial temperature of 2°C.

#### 7.5.2. Corning® (formerly BioCision®) CoolCell®

7.5.2.1. Make sure that all parts of the CoolCell®, including the central ring, return to room temperature (15 to 25°C or up to 30°C, depending on climatic conditions) between uses.

#### 7.5.3. Nalgene® Mr. Frosty™, 1°C/minute cryo-freezing container

7.5.3.1. Mr. Frosty™ should be stored at ambient temperature (15 to 25°C or up to 30°C, depending on climatic conditions) between uses.

7.5.3.2. The isopropanol level must be correct, and the isopropanol must be completely replaced after the fifth freeze-thaw cycle. A log must be used to track freeze/thaw cycles and reagent changes. See Appendix C.

#### 7.5.4. Control-rate freezer, such as CryoMed® Freezing Chamber (Gordinier). (Note for HVTN: Controlled-rate freezers are not allowed for HVTN samples.)

## 8. Disposables

### 8.1. Plastics

8.1.1. Serological pipets, disposable, 1, 5, 10, 25, 50mL, sterile

8.1.2. Micropipette tips, 20, 100, 200, 1000µL, sterile

8.1.3. 15 and 50mL disposable centrifuge tubes, sterile, conical bottom, graduated, polypropylene.

8.1.4. 50mL cell separation tubes with frit barriers (CSTFB), dry (not purchased as pre-filled with cell separation media).

8.1.4.1. Required for HVTN processing. Review LPC/SPLI/LM for protocol specific requirements for all networks.

8.1.5. Cryogenic vials (cryovials) with internal threads, 1.8mL to 2mL, screw cap with o-ring, sterile, polypropylene only, self-standing, graduated, leak-proof, formulated for vapor-phase LN<sub>2</sub> preservation (approximately -140°C). Confirm acceptability of any substitutions for cryogenic vials with the network(s) before purchase (See Appendix F).

**Note:** Snap cap tubes *must not* be used. Additionally, cryovials must not be filled beyond the capacity specified by the manufacturer or to the top of the tube.

8.1.6. Optional: Sterile bottles/flasks, disposable, 45mm neck, 250 to 500 mL for pooling large volume whole blood draws before PBMC separation.

8.1.7. Optional: 5mL sterile, individually wrapped plastic transfer pipets

8.1.8. Optional: Pre-filled 50mL cell separation tubes with frit barriers (CSTFB).

**Note for HVTN:** Not optional for HVTN studies, HVTN requires that laboratories purchase "dry" CSTFB (i.e., not purchased as pre-filled); use of other CSTFB must be pre-approved by the HVTN Lab Center.)

### 8.2. Markers

**Note:** Markers for writing on processing tubes and vials should have a fine point, and contain fast drying, indelible ink.

### 8.3. Labels

**Note:** Cryogenic labels and ink must be suitable for -80°C or LN<sub>2</sub> vapor phase storage temperatures.



**9. Personal Protective Equipment**

Note: Personal protective equipment suitable for use with bloodborne pathogens is required. Follow local laboratory guidelines and practices for the handling of blood products.

- 9.1. Laboratory coat or gown
- 9.2. Eye protection
- 9.3. Non-powdered, nitrile gloves or equivalent
- 9.4. Cryogloves
- 9.5. Face shields (with chin cap if preferred or required by local biosafety regulations), required when working with LN<sub>2</sub>.

**10. Reagents**

10.1. The purchase of sterile reagents and use of aseptic techniques are required.

- 10.1.1. Store opened bottles at the temperature recommended by the manufacturer until fully consumed, until instructed to discard below, or until manufacturer’s expiration date whichever comes first.
- 10.1.2. See Appendix F for recommended products
- 10.1.3. Discard if visible signs of contamination, such as a cloudy appearance, develop.

10.2. Wash Diluent Reagents (WDR)

- 10.2.1. 1X Hanks’ Balanced Salt Solution (HBSS) without calcium or magnesium, ready-to-use
- 10.2.2. 1X Phosphate-Buffered Saline (PBS) without calcium or magnesium, ready-to-use.

10.3. Density Gradient Media (density 1.077 g/mL)

- 10.3.1. Ready to use sterile medium for high yield isolation of human lymphocytes from peripheral blood
- 10.3.2. See Appendix F for recommended products

10.4. Cell Separation Tube with Frit Barrier (CSTFB, if used). Required for HVTN unless alternative noted in protocol-specific SPLI/LPC/LM.

10.4.1. Non-filled CSTFB System (combine a dry CSTFB with 1.077 density gradient media)

- 10.4.1.1. Bring density gradient media (DGM) to room temperature (15 to 25°C or up to 30°C, depending on climatic conditions). Protect from light.
- 10.4.1.2. Work in the BSC following aseptic technique
- 10.4.1.3. Record related CSTFB and DGM information directly from the package or bottle used onto the PBMC worksheet. CSTFBs prepared in advance must have labels including all required information, date of preparation and initials of person who prepared the tubes.
- 10.4.1.4. Prepare tubes by pipetting the volume of DGM appropriate for the size of CSTFB tube being used (as noted below).

Tube capacity (mL)	Density gradient media volume (mL)
50mL	15mL

- 10.4.1.5. Cap the CSTFBs with DGM added and centrifuge at 800 x g for 30 seconds (or lowest time setting above 30 seconds) at room temperature (15 to 25°C or up to 30°C, depending on climatic conditions).
- 10.4.1.6. The DGM should now be below the frit barrier. Inspect tubes for gaps or large bubbles between the DGM layer and the frit barrier or for DGM remaining above the frit.
- 10.4.1.7. If there are gaps or large bubbles below the frit, add additional media, centrifuge the CSTFB again at 800-1000 x g for 30 seconds to 1 minute (select lowest centrifuge setting) and re-inspect.
- 10.4.1.8. If there is liquid (DGM) above the frit, centrifuge the CSTFB again at 800-1000 x g for 30 seconds to 1 minute (select lowest centrifuge setting). If any density gradient solution remains above the frit after re-centrifuging, remove it following aseptic technique.



## Cross-Network PBMC Processing Standard Operating Procedure

10.4.1.9. Follow density gradient media manufacturer's storage recommendations.

10.4.2. Pre-filled CSTFB (1.077 density gradient media)

Note: The capacity of the tube required will depend on the whole blood volume. Store in the refrigerator (2 to 8°C).

Note for HVTN: CSTFB purchased as pre-filled are not allowed.

- Protect from light.
- A cloudy appearance indicates deterioration of the product. Discard if visible signs of contamination are noted.
- Allow pre-filled CSTFB to come to room temperature (15 to 25°C or up to 30°C, depending on climatic conditions) prior to use.

### 10.5. Freezing Reagents

10.5.1. Fetal Bovine Serum (FBS), heat-inactivated required. (See Section 11.1 Heat-Inactivated FBS for handling and management details).

Note for HVTN and HVTN-HPTN joint studies: HVTN-approved FBS is provided to labs by the network and must not be purchased outside of the HVTN supply chain/process.

Note for HVTN-ACTG joint studies: This will be determined on a protocol by protocol basis.

Note for ACTG studies: There are limited approval FBS lots. Refer to <https://www.actg-impact-lc.org> under resources > documents for current FBS ordering information and list of approved lots. Please ensure that the FBS manufacturer, lot number, and expiration date is entered into LDMS.

10.5.1.1. Check with applicable network(s) for preferred vendors.

10.5.1.2. Obtain a certificate of analysis from the vendor for local laboratory quality control records.

Note: A copy of the FBS certificate of analysis may be required to export (or import) PBMC aliquots between countries.

10.5.1.3. FBS stored frozen ( $\leq -20^{\circ}\text{C}$ /according to manufacturer's recommendations) is good until the manufacturer's expiration date.

10.5.1.4. FBS thawed and stored at 2 to 8°C is stable for one calendar month.

10.5.2. Dimethylsulfoxide (DMSO), cell-culture grade

10.5.2.1. Use cell-culture grade DMSO.

10.5.2.2. Store unopened bottles at room temperature (15 to 25°C or up to 30°C, depending on climatic conditions). Check bottle for expiration date and discard if expired.

10.5.2.3. Once opened, undiluted DMSO, when protected from light and moisture, is stable at room temperature (15 to 25°C or up to 30°C, depending on climatic conditions) for 6 months (or until the manufacturer's expiration date if that date is < 6 months from the date of opening). Correct the label on the bottle to reflect the new expiration date.

10.5.2.4. Use aseptic technique when removing DMSO from the bottle to avoid possible contamination.

10.5.2.5. Discard contents of open bottle if visible signs of contamination are noted.

10.5.2.6. Reagents may be aliquoted in small amounts to help preserve sterility. Label aliquots with "DMSO," manufacturers name, lot number, the date opened/aliquoted, the expiration date (six months from opening or expiration date from original bottle whichever is sooner) and tech initials. Protect aliquots from light.

10.5.3. Disinfectant

10.5.3.1. 70% v/v ethanol disinfectant, spray bottle

10.5.3.2. 10% v/v bleach, bucket or beaker and spray bottle (must be made daily)

10.5.3.3. Other disinfectant as specified by local laboratory policy



### 10.6. Cell Counting Reagents

**Note:** The requirements for counting reagents will vary depending on the method used. Refer to the network approved SOP/instructions for the method being used. Use of glacial acetic acid is not permitted for HVTN manual counts.

10.6.1. 0.4% Trypan blue solution

10.6.2. Optional: 0.05% crystal violet solution can be used to stain the cell nucleus so mononuclear cells can be identified and counted using a hemacytometer. If viability is required, a second manual count using trypan blue must be performed. 0.05% Crystal Violet Solution contains: 0.05 g crystal violet, 2mL glacial acetic acid, and 98mL distilled or deionized H<sub>2</sub>O.

## 11. Reagent Preparation

### 11.1. Heat-Inactivated FBS (HI-FBS)

**Note:** HI-FBS can be ordered from the manufacturer, or FBS can be ordered from the manufacturer and heat inactivated in the lab. Follow these instructions for thawing, aliquoting and use.

**Note for HVTN:** HVTN-approved FBS is provided to labs by the network as heat inactivated. HVTN-approved FBS must be requested through the HVTN FBS supply chain/process.

11.1.1. Remove the FBS from the freezer.

11.1.2. Thaw in the refrigerator (2 to 8°C), preferred, or for several hours at room temperature (15 to 25°C or up to 30°C, depending on climatic conditions). Do not allow FBS to sit at room temperature any longer than necessary to complete the thawing process.

11.1.3. Gently swirl two or three times over the course of the thaw.

11.1.4. Follow these additional instructions if the FBS was not heat inactivated. If the FBS was heat inactivated by the manufacturer, skip to 11.1.5.

11.1.4.1. Place FBS in a 56°C (55 to 57°C) water bath. Carefully monitor the water bath temperature. Higher temperatures can degrade components of the FBS.

**Note:** The water level in the water bath should cover the level of the FBS in the bottle, but not touch the cap of the bottle. This will help ensure even heating of the FBS and avoid contamination.

11.1.4.2. Once the water bath has returned to 56°C (55 to 57°C), heat the FBS for 30 minutes, mixing every 5 to 10 minutes. Heating for longer periods of time can degrade components of the FBS.

**Note:** Clean the bottle with 70% v/v ethanol before opening.

11.1.5. Mix the HI-FBS gently but thoroughly using aseptic technique.

11.1.6. Aliquot into sterile, labeled, 50mL sterile, conical bottom, graduated polypropylene centrifuge tubes, or other size aliquots appropriate for the anticipated workload.

**Note:** Labels should identify these tubes as "HI-FBS" and include the manufacturer's name, lot number, the aliquot date, storage conditions, the original manufacturer's expiration date, and the technician's initials. FBS is stable for 1 month (if 1 month period does not exceed original manufacturer's expiration date) at 2 to 8°C, or until the original manufacturer's expiration date if kept at -20°C. Remember to update the expiration date and storage conditions on aliquots/bottles removed from -20°C storage for use.

11.1.7. Refrigerate (2 to 8°C) the number of aliquot tubes needed for the expected workload. Mix well before use. The aliquot tubes that are not immediately needed should be frozen and are stable until the original manufacturer's expiration date.

**Note:** Repeated freeze/thaw cycles will have an adverse effect on the quality of the FBS. Do not refreeze aliquots that have been stored at refrigerated temperatures.

11.1.7.1. To use the frozen aliquots, thaw in advance in the refrigerator overnight, preferred, or at room temperature (15 to 25°C or up to 30°C, depending on climatic conditions) for several hours. Do not allow FBS to sit at room temperature any longer than necessary to complete the thawing process.



## Cross-Network PBMC Processing Standard Operating Procedure

11.1.7.2. Once thawed, FBS is stable for 1 month at 2 to 8°C, or expiration date from original bottle, whichever is sooner. Remember to update the expiration date and storage conditions on aliquots/bottles removed from -20°C storage for use. Mix well before use.

### 11.2. Fresh Cryopreservation Solution (CPS)

#### 11.2.1. CPS Components

Components	Percent (v/v)
DMSO	10%
FBS (heat-inactivated)	90%

11.2.2. For CPS preparation, use Method 1 for HVTN and HPTN, and Method 2 for ACTG.

*Note for ACTG:* When using Method 2 for ACTG, proceed directly to Section 11.2.7.

#### 11.2.3. Method 1: CPS Preparation for HVTN/HPTN

*Note:* This is the traditional HANC/current HVTN and HPTN method of estimating CPS volume needed in advance of processing. Use when target cells per vial (N1) and final aliquot volume (V2) are defined, but number of aliquots varies depending on the total number of cells harvested.

- 11.2.3.1. Use sterile, labeled, disposable 15mL or 50mL conical centrifuge tube(s) to hold prepared CPS.
- 11.2.3.2. Prepare CPS in advance, ideally prior to the start of processing, and chill in the refrigerator (2 to 8°C). CPS can be stored at 2 to 8°C for up to 1 working day (<18 hours).

*Note:* Mixing DMSO and FBS is an exothermic reaction. Record the time of CPS batch placement in the refrigerator and ensure a minimum of 30 minutes of chilling at 2 to 8°C has passed before using. If CPS is urgently needed, chill in an ice bath (wet ice and water) for a minimum of 15 minutes prior to use.

- 11.2.3.3. CPS must be maintained at 2 to 8°C to avoid damage to cells. Do not use CPS that has not met the minimum requirement for chilling noted above
- 11.2.3.4. Use the formula below to estimate the volume of CPS to prepare in advance for final resuspension of PBMC when number of aliquots is variable. Examples are shown below.

$$\text{Maximum Whole Blood Volume (mL)} \times \text{Cell Yield (cells/mL)} \times \text{Freeze-down Concentration (mL/cells)} = \text{Estimated CPS (mL)}$$

**Round this result up to the next whole mL**

***Note:***

For Maximum whole blood volume: Use the maximum possible total volume of whole blood to be processed. Multiply the number of tubes scheduled for collection by the total volume capacity, blood + liquid anticoagulant, of each tube to get this total. (i.e. consider each 10 mL NaHep tube, 10mL EDTA tube and 8.5mL ACD tube (8.5mL whole blood capacity + 1.5mL liquid anticoagulant) to have a 10mL volume capacity).

For Cell Yield: Use an average adult yield of 1.5 million cells/mL as a default. Exceptions may be made when warranted, (i.e. participant known to have cell yield above 3.0 million cells/mL).

For freeze-down concentration: Use the final aliquot volume (V2) and the target number of cells per aliquot (N1) defined in the protocol specific SPLI/LPC/LM. Record as V2/N1.

Monitor CPS daily usage to maximize efficiency and minimize waste and adjust as needed. For example, if the calculation yields CPS volumes that are regularly not sufficient, i.e., multiple



## Cross-Network PBMC Processing Standard Operating Procedure

batches must be made to complete processing, consider increasing the final volume by a fixed percentage such as 20% and round **up** to the next whole mL.

**Examples:** Adult Blood—Daily CPS batch - multiple visits scheduled:

- Target Freeze-down Concentration (mL/cells) for all is (1.0mL/15 x 10<sup>6</sup> cells) or 15 million cells (N1) frozen in 1mL (V2) of CPS.
- Calculate total maximum expected whole blood volume:

**Note:** Remember to include the liquid anticoagulant when calculating maximum total volumes from ACD tubes. NaHep and EDTA tubes do not have liquid anticoagulants so the tube volume as recorded on the laboratory requisition is the maximum possible volume.

- First scheduled visit includes 18 x 8.5mL ACD tubes for PBMC processing
- Second scheduled visit includes 8 x 8.5mL ACD tubes for PBMC processing
- Third scheduled visit includes 8 x 10.0mL NaHep tubes for PBMC processing
- Total tubes expected (18+8+8) = 34, 34 tubes x 10.0mL = 340.0mL maximum expected volume

Usable Whole Blood x	Cell Yield x	Freeze-down Concentration =	Estimated CPS to Prepare
(340.0mL) x	(1.5 x 10 <sup>6</sup> cells/1mL) x	(1.0mL/15 x 10 <sup>6</sup> cells) =	34.0mL

**Example:** Adult Blood—One Large Volume Blood Collection. Target Freeze-down Concentration (mL/cells) is (1.0mL/15 x 10<sup>6</sup> cells) or 15 million cells frozen in 1mL (V2) of CPS. CPS batch created after UWBV was measured.

Usable Whole Blood x	Cell Yield x	Freeze-down Concentration =	Estimated CPS to Prepare
(135.0mL) x	(1.5 x 10 <sup>6</sup> cells/1mL) x	(1.0mL/15 x 10 <sup>6</sup> cells) =	14.0mL

**Example:** Adult Blood—8 x 10.0mL NaHep Blood Collection. Target Freeze-down Concentration (mL/cells) is (1.0mL/10 x 10<sup>6</sup> cells) or 10 million cells (N1) frozen in 1mL (V2) of CPS. CPS batch created before UWBV was measured.

Usable Whole Blood x	Cell Yield x	Freeze-down Concentration =	Estimated CPS to Prepare
(80.0mL) x	(1.5 x 10 <sup>6</sup> cells/1mL) x	(1.0mL/10 x 10 <sup>6</sup> cells) =	12.0mL

11.2.4. Use the following formula to calculate the amount of DMSO and FBS needed.

$$CPS = 1 \text{ part DMSO} + 9 \text{ parts FBS}$$

**Examples:**

Estimated CPS Volume	DMSO Volume = (.1)(CPS volume)	HI-FBS Volume = CPS volume – DMSO volume	Total CPS Volume = DMSO volume + FBS volume
10.0ml	1.0mL	9.0mL	10.0mL
5.0ml	0.5mL	4.5mL	5.0mL

11.2.5. Record the CPS, DMSO and FBS volumes on the PBMC worksheet. It is recommended that the date and time of creation and initials of person creating the batch be captured on the worksheet and conical tube as well.

11.2.6. If secondary batches are created to complete processing, remember to capture the same details for the additional batch, including the method/time of chilling, on the worksheet.



## Cross-Network PBMC Processing Standard Operating Procedure

### 11.2.7. Method 2: CPS Preparation for ACTG

**Note:** This is the ACTG method of estimating CPS volume. Use when maximum number of aliquots for each visit and final aliquot volume (V<sub>2</sub>) are defined.

- 11.2.7.1. Use sterile, labeled, disposable 15mL or 50mL conical centrifuge tube(s) to hold prepared CPS.
- 11.2.7.2. Prepare CPS in advance, ideally prior to the start of processing, and chill in the refrigerator (2 to 8°C). CPS can be stored at 2 to 8°C for up to 1 working day (<18 hours)

**Note:** Mixing DMSO and FBS is an exothermic reaction. Record the time of CPS batch placement in the refrigerator and *ensure a minimum of 30 minutes* of chilling at 2 to 8°C has passed before using. If CPS is urgently needed, chill in an ice bath (wet ice and water) for a *minimum of 15 minutes prior to use*.

- 11.2.7.3. CPS must be maintained at 2 to 8°C to avoid damage to cells. Do not use CPS that has not met the minimum requirement for chilling noted above.
- 11.2.7.4. Determine the volume required based on protocol mandated maximum number of aliquots per visit or additional batch volume required to meet current V<sub>f</sub> needed.
- 11.2.7.5. Add additional 10-20% to CPS volume required to account for potential loss during mixing/pipetting steps and round the result UP to the next whole number.
- 11.2.7.6. Scenario A: Fixed maximum number of aliquots per visit.

**Example:** Lab schedule has two PBMC visits requiring a maximum allowable number of aliquots of four per visit. The protocol specific volume per aliquot (V<sub>2</sub>) is 1.0mL. Total of eight aliquots maximum for the day. Multiply number of aliquots by V<sub>2</sub> to determine required FBS. Add additional volume, such as 10%, to account for loss during mixing/pipetting. Round UP to next whole number for final CPS volume to make.

(8 x 1.0mL = 8.0mL, 8.0mL x 1.1 = 8.8mL. Round up to final volume of 9.0mL)

- 11.2.8. Use the formula below to calculate the amount of DMSO and FBS needed.

$$CPS = 1 \text{ part DMSO} + 9 \text{ parts FBS}$$

**Examples:**

Estimated CPS Volume	DMSO Volume = (.1)(CPS volume)	HI-FBS Volume = CPS volume – DMSO volume	Total CPS Volume = DMSO volume + FBS volume
10.0ml	1.0mL	9.0mL	10.0mL
5.0ml	0.5mL	4.5mL	5.0mL

- 11.2.9. Record the CPS, DMSO and FBS volumes on the PBMC worksheet. It is recommended that the date and time of creation and initials of person creating the batch be captured on the worksheet and conical tube as well.
- 11.2.10. If secondary batches are created to complete processing, remember to capture the same details for the additional batch including the method/time of chilling on the worksheet.

## 12. PBMC Processing Introduction and Guidelines

There are standard principles and steps common to all PBMC processing procedures. Variations occur with the choice of separation techniques (CSTFB versus manual overlay), the treatment of the blood (dilution with or without plasma replacement versus direct plasma harvest), final cell concentration, and freezing/storage. Select the appropriate procedure sections for cell separation and blood treatment, and freezing and storage based on network and protocol



requirements.

**13. Cell Separation and Blood Dilution by Cell Separation Tube with Frit Barrier (CSTFB) with Plasma Replacement**

Section 13 can be used for all networks; check protocol requirements and available materials. For any given sample, use either Section 13 or Section 14, but not both.

- 13.1. Separation of lymphocytes from peripheral blood using CSTFB separation tubes with room temperature (15 to 25°C or up to 30°C, depending on climatic conditions) density gradient media (DGM) added.
  - 13.1.1. Perform all pipetting and mixing in a Class II biosafety cabinet (BSC) level 2 or higher.
  - 13.1.2. Spray down all surfaces, racks, and reagent bottles with 70% v/v ethanol or equivalent disinfectant each time prior to entering and using the BSC.
  - 13.1.3. Unless otherwise noted, the procedure is carried out at room temperature (15 to 25°C or up to 30°C, depending on climatic conditions).
  - 13.1.4. Use a new pipet for each participant identification number (PTID) and additive.
- 13.2. Prepare whole blood samples, reagents, and supplies.
  - 13.2.1. Prepare and chill the CPS (see Section 11 Reagent Preparation) prior to processing or sufficiently in advance of mixing with PBMC if additional CPS is needed.
 

*Note:* CPS batches should be prepared in advance of beginning specimen processing steps. Batch volumes must be monitored and creation of additional batches, when needed, captured in full detail on the PBMC worksheet.
  - 13.2.2. Prepare enough CSTFB tubes to manage the maximum amount of blood expected.
    - 13.2.2.1. For 50mL CSTFB tubes, plan for a maximum volume of 20mL, or one CSTFB for every two 8.5-10.0mL blood collection tubes. Tip: Divide the total number of 8.5-10.0mL collection tubes to be received by 2. If the result is a fraction, (an odd number of blood collection tubes), round up to the nearest whole number (i.e. add an additional CSTFB tube).
    - 13.2.2.2. Examples:
      - Visit 1 has 3 x 10.0mL NaHep tubes. Prepare 2 CSTFB tubes.
      - Visit 10 has 10 x 8.5mL ACD tubes. Prepare 5 CSTFB tubes
  - 13.2.3. Ensure that the prepared CSTFB tubes containing DGM are at room temperature (15 to 25°C or up to 30°C, depending on climatic conditions) before starting processing steps.
  - 13.2.4. Visually inspect the filled CSTFB tubes to confirm no large bubbles, gaps exist between the DGM and frit barrier and that no DGM is present above the frit before adding the WDR or blood to the tubes. (See CSTFB preparation instructions in Section 10.4 for instructions on managing DGM volume issues when noted).
  - 13.2.5. Gather the same number of new 50mL sterile, conical bottom, graduated polypropylene centrifuge tubes as CSTFB prepared (see Section 13.2.2) for use. These “wash” tubes will be used for the harvested cells and subsequent wash steps.

CSTFB Size (mL)	Conical Centrifuge Tube Size (mL)
50	50

- 13.2.6. If plasma replacement is required, gather a 15 or 50mL sterile, conical bottom, graduated polypropylene centrifuge tube appropriate for the required volume of plasma to be harvested. Label with PTID, anticoagulant, and derivative.
- 13.2.7. If the specimen tubes are cold to the touch (due to cold ambient conditions such as transport in cooler months), allow the tubes to reach room temperature (15 to 25°C or up to 30°C, depending on climatic conditions) before processing
- 13.2.8. Carefully check the PTID on all tubes of blood received. Organize primary tubes such that there is no



## Cross-Network PBMC Processing Standard Operating Procedure

possibility of mixing tubes between PTID/PIDs or anticoagulants.

**Suggestion:** Place all tubes for each PTID/anticoagulant in one rack. Different racks can be used to separate PTIDs or tube types and use different colored markers for each PTID to avoid confusion.

### 13.3. Plasma Replacement

**Note:** Perform this plasma replacement step only if plasma aliquots are required from the PBMC collection tubes per the protocol or SPLI/LPC/LM; proceed to step 13.4 if plasma aliquots are not required.

- 13.3.1. Blood collection tubes from the same PTID and same anticoagulant must be processed individually (not pooled in 50mL conical centrifuge tubes) unless otherwise indicated in the protocol specific SPLI/LPC/LM.
- 13.3.2. Mark the whole blood volume on each collection tube at the meniscus.
- 13.3.3. Centrifuge the whole blood at 200 to 400 x g for 10 minutes. Record processing start time on the PBMC worksheet.
- 13.3.4. Transfer plasma to a labeled 15 or 50mL conical centrifuge tube for second centrifugation to remove any cellular debris.
- 13.3.5. Add a quantity of WDR sufficient to bring blood back to its original whole blood volume, mix gently and continue PBMC processing at step 13.4.
- 13.3.6. Complete the plasma processing by centrifuging the collected plasma at 800 to 1200 x g for 10 minutes to obtain PL2 aliquots or according to protocol or SPLI/LPC/LM. This step may occur later when the centrifuge is not in use for PBMC processing.
- 13.3.7. Aliquot double spun plasma into labeled aliquot tubes as specified by protocol specific SPLI/LPC/LM and discard remaining cellular debris.

### 13.4. Blood Dilution for CSTFB separation

**Note:** Use one 50mL tube for each 12 to 20mL of whole blood. Use as many CSTFB tubes as required to distribute all the blood for each PID/PTID.

**Note:** Density gradient media is toxic to cells; work quickly and efficiently during the separation steps.

- 13.4.1. Label each CSTFB and corresponding sterile conical centrifuge “wash” tube with the PTID (and anticoagulant if appropriate)
- 13.4.2. Using a sterile serological pipet, add WDR to each labeled, prepared CSTFB:

CSTFB Size (mL)	Approximate Volume of WDR (mL)
50	5

- 13.4.3. Using a sterile serological pipet, add WDR to each pre-labeled, sterile conical centrifuge “wash” tube:

CSTFB Size (mL)	Conical Centrifuge Tube Size (mL)	WDR Pre-Fill Volume (mL)
50	50	25

- 13.4.4. Uncap the tubes of anti-coagulated blood. If plasma replacement steps were not required/performed, record the time of cap removal as processing start time on the PBMC worksheet.
- 13.4.5. If the blood in a collection tube is clotted or grossly hemolyzed, see Section 6.3.
- 13.4.6. Use a sterile serological pipet to mix the whole blood gently then transfer the blood into the labeled CSTFBs.

**Note:** Blood must be transferred using a 10mL serological pipet, in measured quantities of 10.0mL until less than 10.0mL remains. Distribute the blood across CSTFB tubes in fixed increments to ensure accurate tracking of volumes for UWBV measurement throughout the distribution of whole blood.

- 13.4.7. Target transfer of 15 – 20mL total amount of blood to each labeled CSTFB. (The expanded range below is allowable only in certain situations where the target range is not possible). Do not start to fill a new 50mL CSTFB unless a minimum of 12mL of blood is available/remaining.

CSTFB Size (mL)	Approximate Volume of Blood (mL)*
50	15-20 (12 to 22 allowable in certain scenarios)

\*Lower blood volumes, especially in the presence of low hematocrits, may cause the

buffy coat to drop close to/onto the frit, making it difficult to harvest. Higher blood volumes may contribute to increased background/debris in specimens. Refer to protocol-specific guidelines for lower blood draw volumes.

13.4.8. Determine and record an accurate measurement of the usable whole blood volume within 0.1mL.

*Note:* the volume of usable whole blood is not necessarily equal to the tube size.

13.4.9. Using a sterile pipet, rinse each original anti-coagulated blood tube with WDR, add rinse volumes to the CSTFB making sure not to exceed the total tube volume (WDR + Whole Blood) limit.

CSTFB Size (mL)	Total Tube Volume Limit (mL) (Whole Blood +WDR)
50	30

13.4.10. Carefully cap the CSTFB.

### 13.5. CSTFB density centrifugation and collection

13.5.1. Hold the tubes in an upright position, place them in a rack and transfer them to the centrifuge.

13.5.2. Centrifuge at 800 to 1000 x g for 15 minutes at 15 to 25°C (or up to 30°C, depending on climatic conditions) with the Brake OFF/set to zero.

*Note:* If the brake is on, it will disrupt the layers.


13.5.3. While the CSTFB tubes are spinning, discard all emptied collection tubes following laboratory practices, clean the BSC surface and organize for the next steps.

13.5.4. Confirm the correct number of labeled, sterile conical centrifuge tubes pre-filled with WDR (“wash” tubes) are ready in the BSC for the harvesting/wash steps.

13.5.5. Once the centrifuge comes to a complete stop, gently remove each CSTFB from the centrifuge so as not to disturb the layers. Use a rack to support the tubes and carefully transfer to the BSC.

13.5.6. Centrifugation results in the tube contents dividing into six distinct layers including the frit. From the top of the tube, these are:

- Plasma + WDR
- PBMC layer
- Density gradient media (DGM)
- Frit
- Density gradient media (DGM)
- Packed red blood cells (RBC) and granulocytes



13.5.7. Inspect the tubes for the following potential problems. Document observations and any follow-up actions taken according to network and laboratory requirements.

- Hemolysis in the Plasma + WDR layer
- Clots visible on the frit after centrifugation.
- Poor PBMC layer due to errors in centrifugation such as speed time or braking. PBMC layer will appear small and indistinct while Plasma + WDR layer may be slightly cloudy. Refer to Appendix D for troubleshooting.
- PBMC layer formed on frit due to low RBC count or hematocrit volume.
- RBC layer immediately below and touching the PBMC layer.



## Cross-Network PBMC Processing Standard Operating Procedure

- 13.5.8. Using a new sterile serological pipet for each PTID, remove the upper yellowish, plasma-WDR fraction down to within 1 to 2 cm of the cloudy white PBMC band located at the interface between the plasma-WDR (yellowish) fraction and the clear separation medium solution. Be careful not to disturb the cell layer during this process. Discard the plasma-WDR fraction per laboratory policy.  
*Note:* Alternatively, the cloudy white PBMC band may be removed by carefully inserting the pipet through the upper plasma-WDR layer.
  - 13.5.9. Using a sterile serological pipet, collect all cells at the cloudy white interface above the frit. Take care not to aspirate any more density gradient medium than necessary.
    - 13.5.9.1. Transfer the collected cells from one CSTFB to a single corresponding, pre-labeled, sterile conical centrifuge “wash” tube (prepared as noted in Section 13.4). Tubes are pre-filled with WDR to save time.
  - 13.5.10. Re-cap the CSTFB containing the remaining red blood cells and separation media. Discard the CSTFB as biohazardous waste following laboratory policy.
- 13.6. Ensure that all key elements are recorded according to network and laboratory requirements. Proceed to Section 15.

### 14. Cell Separation by Manual Density Gradient Media Overlay or Underlay and Blood Dilution by Manual Density Gradient Cell Separation with Plasma Replacement

Section 14 can be used for all networks; check protocol requirements and available materials. For any given sample, use either Section 13 or Section 14, but not both.

*Note for HVTN:* HVTN does not recommend use of the underlay method. Pre-approval of the underlay method must be obtained from the HVTN Lab Center before use for protocol specimens.

- 14.1. Separation of lymphocytes from peripheral blood using Manual Density Gradient Media Overlay Method
  - 14.1.1. Perform all pipetting and mixing in a Class II biosafety cabinet (BSC) level 2 or higher.
  - 14.1.2. Spray down all surfaces, racks, and reagent bottles with 70% v/v ethanol each time prior to entering and using the BSC.
  - 14.1.3. Unless otherwise noted, the procedure is conducted at room temperature (15 to 25°C or up to 30°C, depending on climatic conditions).
  - 14.1.4. Use a new pipet for each participant identification number (PTID) and additive.
- 14.2. Prepare whole blood samples, reagents, and supplies
  - 14.2.1. Prepare and chill the CPS (see Section 11 Reagent Preparation) prior to processing or sufficiently in advance of mixing with PBMC if additional CPS is needed.  
*Note:* CPS batches should be prepared in advance of beginning specimen processing steps. Batch volumes must be monitored and creation of additional batches, when needed, captured in full detail on the PBMC worksheet.
  - 14.2.2. Allow the density gradient media to come to room temperature (15 to 25°C or up to 30°C, depending on climatic conditions). See Section 10 Reagents for more information.
  - 14.2.3. Gather enough 50mL sterile, conical bottom, graduated polypropylene centrifuge tubes to manage all dilution, overlay/underlay and wash steps.
  - 14.2.4. If plasma replacement is required, gather a 15 or 50mL sterile, conical bottom, graduated polypropylene centrifuge tube appropriate for the required volume of plasma to be harvested. Label with PTID, anticoagulant, and derivative.
  - 14.2.5. If the specimen tubes are cold to the touch (due to cold ambient conditions such as transport in cooler months), allow the tubes to reach room temperature (15 to 25°C or up to 30°C, depending on climatic conditions) before processing.



## Cross-Network PBMC Processing Standard Operating Procedure

14.2.6. Carefully check the PTID on all tubes of blood received. Organize primary tubes such that there is no possibility of mixing tubes between PTIDs or anticoagulants within a PTID collection.

Suggestion: Place all tubes for each PTID/anticoagulant in one rack. Different racks can be used to separate PTIDs or tube types, and a different color of marker can be used for each PTID to avoid confusion.

14.2.7. Determine and record an accurate measurement of the usable whole blood volume within 0.1mL using a 10mL serological pipet (or other network approved method). As a reminder, the volume of usable whole blood is not necessarily equal to the tube size.

Note for HVTN: The use of reference tubes or conical tubes for the purposes of measurement is not allowed.

### 14.3. Plasma Replacement

Note: Perform this plasma replacement step only if plasma aliquots are required from the PBMC collection tubes per the protocol or SPLI/LPC/LM; proceed to step 14.4 if plasma aliquots are not required.

14.3.1. Blood collection tubes from the same PTID and same anticoagulant may be processed individually or pooled in 50mL conical centrifuge tubes (pooling not allowed for HVTN).

14.3.2. Mark the whole blood volume on each collection tube at the meniscus.

14.3.3. Centrifuge the whole blood at 200 to 400 x g for 10 minutes. Record processing start time on the PBMC worksheet.

14.3.4. Transfer plasma to a labeled 15 or 50mL conical centrifuge tube for second centrifugation to remove any cellular debris.

14.3.5. Add a quantity of WDR sufficient to bring blood back to its original whole blood volume, mix gently and continue PBMC processing at step 14.4.

14.3.6. Complete the plasma processing by centrifuging the collected plasma at 800 to 1200 x g for 10 minutes to obtain PL2 aliquots or according to protocol specific SPLI/LPC/LM . This step may occur later when the centrifuge is not in use for PBMC processing.

14.3.7. Aliquot double spun plasma into labeled aliquot tubes as specified by protocol specific SPLI/LPC/LM and discard remaining cellular debris.

### 14.4. Blood Dilution for Manual Density Gradient Cell Separation

14.4.1. Uncap the tubes of anti-coagulated blood. If plasma replacement steps were not required/performed, record the time of cap removal as processing start time on the PBMC worksheet.

14.4.2. If a tube is grossly clotted or grossly hemolyzed, see Section 6.3.

Note: The pooling of buffy coats is allowed according to the guidelines in Appendix E: Pooling Buffy Coat Layers for Density Gradient Media PBMC Isolation. To pool buffy coats, replace steps 14.4.3 and 14.4.4 with the instructions in Appendix E.

14.4.3. Label each conical centrifuge tube with the PTID and anticoagulant.

Conical Centrifuge Tube Size (mL)	Approximate Blood volume (mL)
50	12 to 22
15	4 to 5

14.4.4. Transfer the blood to a sterile, labeled 15 or 50mL conical centrifuge tube and add sufficient volume of WDR to dilute the blood according to the density gradient media package insert (The ratio of WDR to whole blood should ideally be one part WDR and one part whole blood).

### 14.5. For Density Gradient Cell Separation:

Note: Use either the Overlay Method (Section 14.5.1) or Underlay Method (Section 14.5.2), but not both.

#### 14.5.1. Overlay Method:

14.5.1.1. Prepare a labeled sterile conical centrifuge tube for each tube containing diluted blood.

14.5.1.2. Add the appropriate volume of density gradient media to the empty sterile conical centrifuge tubes.



## Cross-Network PBMC Processing Standard Operating Procedure

*Note:* The volume of density gradient media will depend on the ratio of density gradient media to diluted blood recommended by the manufacturer.

14.5.1.3. Carefully and slowly pipet diluted blood on top of the density gradient media.

*Suggestion:* Gently allow the WDR-diluted blood mixture to flow down the side of the tube and pool on top of the density gradient media surface without breaking surface plane.

14.5.1.4. Carefully cap the tubes. Proceed to Section 14.6.

14.5.2. Underlay Method:

14.5.2.1. Mix gently and thoroughly to decrease clumping of the cells during separation.

*Optional:* To either whole blood or blood-WDR, add another volume of WDR equal to the total blood volume.

14.5.2.2. Based on the volume of WDR-diluted blood, determine the volume of density gradient medium required for each tube.

*Note:* The volume of density gradient media will depend on the ratio of density gradient media to diluted blood recommended by the manufacturer.

14.5.2.3. Carefully and slowly pipet density gradient media solution UNDER blood-WDR.

14.5.2.4. Carefully cap the tubes. Proceed to Section 14.6.

14.6. Lymphocyte density centrifugation and collection:

14.6.1. Hold the tubes in an upright position, place them in a rack and gently transfer them to the centrifuge.

14.6.2. Centrifuge at 400 x g for 30 minutes at 15 to 25°C (or up to 30°C, depending on climatic conditions) with the Brake OFF/set to zero, or as outlined in the package insert that accompanies the gradient medium.

*Note:* If the brake is on, it will disrupt the layers. The centrifuge brake must be OFF for the separation to be clean and to maximize retrieval of the PBMCs.

14.6.3. While the conical tubes are spinning, discard all emptied collection tubes following laboratory practices, clean the BSC surface and organize for the next steps.

14.6.4. Label (with the PTID/anticoagulant) the same number and size of new sterile conical centrifuge tubes as conical centrifuge tubes used in the separation centrifugation step. Use these new tubes for the following cell harvest and wash steps.

14.6.5. Using a sterile pipet, add WDR to each pre-labeled, sterile conical centrifuge “wash” tube:

Conical Centrifuge Tube Size (mL)	WDR Pre-Fill Volume (mL)
50	25
15	5

14.6.6. Once the centrifuge comes to a complete stop, gently remove each conical tube from the centrifuge so as not to disturb the layers. Use a rack to support the tubes and carefully transfer to the BSC.

14.6.7. If the cell layer is not visible, confirm that the centrifuge is operating properly. Correct any problems you find. Re-centrifuge the tube. Document the problem and actions taken according to network and laboratory requirements.

14.6.8. Document hemolysis or small clots visible at the cell interface.

*Note:* Look for hemolysis, or clots after centrifugation. Grade hemolysis +1 through +4 based on the description given in the glossary. Record your observations.

14.6.9. Using a new sterile pipet (serological or transfer pipet) for each PTID, remove the upper, yellowish, plasma-WDR fraction down to within 1 to 2 cm of the cloudy white PBMC band located at the interface between the plasma-WDR (yellowish) fraction and the clear separation medium solution. Be careful not to disturb the cell layer during this process. Discard the plasma-WDR fraction per laboratory policy.

*Note:* Alternatively, the cloudy white PBMC band may be removed by carefully inserting the pipet through the upper plasma-WDR layer.

14.6.10. Using a sterile serological or transfer pipet, collect all cells at the cloudy white interface. Take care not to aspirate any more separation medium solution than necessary.

14.6.11. Transfer the collected cells from one conical centrifuge tube to a single corresponding, pre-labeled,



## Cross-Network PBMC Processing Standard Operating Procedure

sterile conical centrifuge tube. Tubes can be pre-filled with WDR to save time (Section 14.6.5).

14.6.12. Re-cap the conical centrifuge tube containing the remaining red blood cells/separation medium and discard the tube as biohazardous waste following laboratory policy.

14.7. Ensure that all key elements are recorded according to network and laboratory requirements. Proceed to section 15.

### 15. Washing, Counting, Resuspension, Concentration, and Overnight Controlled- Rate Freezing

15.1. Wash 1:

15.1.1. QS (bring the volume of the PBMC fraction up) to approximately 45mL (for 50mL conical centrifuge tubes) or 10mL (for 15mL conical centrifuge tubes) by adding WDR. Mix gently.

15.1.2. Re-cap all the conical tubes now containing harvested cells diluted in WDR.

15.1.3. Centrifuge diluted cells at 200 to 400 x g for 10 minutes at 15 to 25°C (or up to 30°C, depending on climatic conditions) low brake optional.

15.1.4. Remove the tubes from the centrifuge and check for the cell pellet.

15.1.4.1. If the cell pellet is not visible, confirm that the centrifuge is operating properly and the correct settings were used. Correct any problems you find. Re-centrifuge the tubes. Document the problem and actions taken according to network and laboratory requirements. If the cell pellet is still not visible after re-centrifuging the tube, continue processing steps and document details on processing worksheet.

15.1.5. Remove and discard the WDR supernatant carefully without disturbing the cell pellet by quickly decanting into the designated liquid waste container in the BSC. Alternative methods such as removal with serological pipet or by aspirating may be used for pellets that are loose or contain large quantities of red blood cells.

15.2. Wash 2:

15.2.1. Resuspend each pellet in a small volume of WDR mixing, gently but thoroughly into a homogenous cell suspension.

Tube Size (mL)	WDR Resuspension Volume (mL)
50	≤ 5
15	≤ 3

15.2.2. Combine the pellet suspensions from the same PTID/anticoagulant. This is the harvested cell tube.

Tube Size (mL)	Number of Pellets Suspensions to Combine	Total Volume (mL)
50	≤ 4	≤ 20
15	≤ 2	≤ 6

15.2.3. Use a small volume of WDR to rinse the tubes from which the pellets were transferred. Collect the WDR rinse in the harvested cell tube.

15.2.4. QS the PBMC fraction by adding WDR and mix gently.

Tube Size (mL)	QS Volume (mL)
50	≤ 45
15	≤ 10

15.2.5. Re-cap the tubes and place the tubes in the centrifuge.

15.2.6. Centrifuge diluted cells at 200 to 400 x g for 10 minutes at 15 to 25°C (or up to 30°C, depending on climatic conditions) low brake optional.

15.2.7. Remove the tubes from the centrifuge and check for the cell pellet.

*Note:* If the cell pellet is not visible, confirm that the centrifuge is operating properly. Correct any problems and re-centrifuge the tube. Document the problem and actions taken according to network and laboratory requirements. If the cell pellet is still not visible after re-centrifuging the tube, continue processing steps and document details on processing worksheet.

15.2.8. Remove and discard the WDR supernatant carefully without disturbing the cell pellet by quickly decanting into the designated liquid waste container in the BSC. Alternative methods such as removal



## Cross-Network PBMC Processing Standard Operating Procedure

with serological pipet or by aspirating may be used for pellets that are loose or contain large quantities of red blood cells.

### 15.3. PBMC Cell Count

- 15.3.1. Determine and record the WDR counting resuspension volume (V) accurate to within 0.1mL. V is important because this is the volume on which the cell count is based.

**Note:** The counting resuspension volume (V) is 20% of the measured usable whole blood volume, rounded to the nearest whole mL (recorded X.0) in almost all cases.

**Example:** Measured usable whole blood volume recorded as 78.6mL. The counting resuspension volume would be 16.0mL ( $78.6 \times 20\% = 15.72$ . 15.72 rounded to the nearest whole number is 16.0mL)

**Examples of scenarios where V may be modified:**

- Calculated V slightly exceeds capacity of the conical tube. UWBV measured and recorded as 255.2mL. 20% rounded to the nearest whole number is 51.0mL. In this scenario, V may be reduced to 45.0mL to allow for safe mixing and subsequent centrifugation in a 50mL conical tube.
  - Participant sample results in very faint cell bands and subsequent significantly small cell pellets. In this scenario, V may be reduced to prevent out of range cell counts.
- 15.3.2. If there is more than one pellet from the same PTID/anticoagulant, use a small measured/tracked amount of WDR to gently resuspend and combine cell pellets into one tube. Using the remaining resuspension volume, rinse the tubes from which the cells were transferred. Add the rinse to the tube containing the cell suspension.
- 15.3.3. Mix cells gently, but thoroughly, immediately prior to sampling for the cell count.
- 15.3.4. Transfer a small volume of the resuspension to a small tube for counting. Follow instrument or counting SOP guidance for appropriate volumes.
- 15.3.5. Follow the SOP for the cell counting method approved at the processing laboratory to determine the cell concentration  $\times 10^6$  per mL.

**Note:** Cells at  $10^3/\mu\text{L} = \text{cells at } 10^6/\text{mL}$ .

**Note:** Automated counts may be run once. Manual counts must count at least the four large corner squares ( $1\text{mm}^2$ ).

- 15.3.6. Calculate the total number of cells using the following formula:

$$T = C \times V$$

T = Total number of cells

C = Concentration ( $10^6/\text{mL}$ ) determined in counting method

V = Counting resuspension volume of WDR in mL

- 15.3.7. Calculate the cell yield in cells/mL of usable whole blood using the formula below.

$$\text{Cell Yield (} 10^6 \text{ cells/mL)} = T / \text{Usable Whole Blood Volume}$$

**Note:** Calculate the cell yield for quality purposes. Refer to Section 16 Quality Control for the expected range of cell yields and troubleshooting tips.

### 15.4. Calculation of final resuspension volume

- 15.4.1. Calculate the CPS freeze-down resuspension volume required by completing the steps below for the target number of cells per vial.

**Note:** The target number of cells per vial varies by network and protocol. Refer to the protocol or protocol specific SPLI/LPC/LM for target final cell concentration information.

- 15.4.2. Calculate the estimated CPS freeze-down resuspension volume (V1) required by using the target number of cells per vial.

**Note:** Confirm adequate volume of CPS is prepared and has been chilled in the refrigerator (2 to 8°C) for a minimum of 30 minutes. Preparation in an ice bath (wet ice with water) for a minimum of 15 minutes prior to use is allowed in emergency situations only.



## Cross-Network PBMC Processing Standard Operating Procedure

$$V1 = (T/N1) \times V2$$

T = Total number of cells

N1 = Target number of cells per vial

V2 = Final aliquot volume in mL

Round V1 down to the nearest whole (1.0) mL to determine  $V_f$ .

- 15.4.3. Calculate the actual number of cells per vial (N2) using the actual CPS freeze-down volume ( $V_f$ ) determined in the previous calculation.

$$N2 = (T/V_f) \times V2$$

N2 = Actual number of cells per vial

T = Total number of cells

V2 = Final aliquot volume in mL (1.0mL unless otherwise directed in protocol-specific documentation).

### 15.5. Labeling

- 15.5.1. Complete the printing, quality control and labeling of the cryovials PRIOR to the final centrifugation.

**Note:** It is important to minimize the time that the cells remain in a pellet.

- 15.5.2. Generate cryovial labels using the LDMS.

15.5.2.1. Follow network laboratory practice for completing the data entry.

15.5.2.2. Proof each derivative type of cryovial label for data entry errors against the laboratory requisition and processing worksheet PRIOR to labeling cryovial.

15.5.2.3. Visually inspect the label barcode and print area for alignment and print quality.

15.5.2.4. Correct any data entry errors in LDMS and re-print labels as needed.

- 15.5.3. Apply the labels on the cryovials so that the contents of the tube are visible.

- 15.5.4. Scan the empty, labeled cryovials in sequential GSID order into the LDMS storage module to ensure that the barcode is scannable; the verification of ability to scan and the assignment of storage locations are combined at this step.

**Note:** Use of Nunc racks to allow for one-handed opening/closing of vials is highly recommended. Cryovial caps may not be placed on any surfaces.

### 15.6. Final Centrifugation

**Note:** If cells are to be frozen as nonviable PBMC Pellets (PEL) and as viable cells, remove the volume of PBMCs needed for creating nonviable cell pellets prior to the final centrifugation step and complete processing of nonviable cell pellets and follow protocol specific instructions for non-viable PBMC pellets.

- 15.6.1. QS (bring up the volume of the cell suspension) to 45mL with WDR and place the conical tube(s) containing the diluted harvested cells in the centrifuge.

- 15.6.2. Centrifuge diluted cells at 200 to 400 x g for 10 minutes at 15 to 25°C (or up to 30°C, depending on climatic conditions) brake optional.

- 15.6.3. Verify that all cryovials are labeled and easily accessible.

**Note:** Pre-chilling vials and/or working on wet ice is allowed.

**Note for HVTN:** Pre-chilling of cryovials and working on wet ice is not preferred and must be approved by the HVTN Lab Center before use with HVTN network samples.

- 15.6.4. Select the controlled-rate freezing unit: StrataCooler®, Mr. Frosty™, CoolCell®. Label freezing unit(s) appropriately to allow laboratory staff to determine contents. Ensure unit is at correct temperature for use at time of vialing and easily accessible just prior to removal of final cell pellets from centrifuge. See section 7.5 for storage and maintenance information.

### 15.7. Aliquoting for cryopreservation

**Note:** The following steps must be performed quickly to preserve cell integrity.

- 15.7.1. Remove and discard the WDR supernatant carefully without disturbing the cell pellet by quickly



## Cross-Network PBMC Processing Standard Operating Procedure

decanting into the designated liquid waste container in the BSC. Alternative methods such as removal with serological pipets or by aspirating may be used for pellets that are loose or contain large quantities of red blood cells.

- 15.7.2. Gently resuspend the cell pellet prior to adding the CPS by flicking, tapping, or pipetting as noted below.
  - 15.7.2.1. HVTN allows resuspension of the pellet using the same measured/tracked volume of CPS as the WDR resuspension volume used to resuspend the pellet(s) in the previous wash steps. Remember to subtract this CPS volume from the total final CPS resuspension volume ( $V_f$ ) to be added if the total final CPS resuspension volume ( $V_f$ ) is greater than the volume used to resuspend the pellet.
  - 15.7.2.2. Gently add the volume of cold CPS ( $V_f$ ) determined in section 15.4 (minus any resuspension volume used to break up the pellet) to the resuspended cells with continuous swirling.
- 15.7.3. Work quickly once the CPS has been added. Do not allow the cells to sit in the cryopreservation solution for longer than 10 minutes before placing them in the freezer.
- 15.7.4. Mix the entire suspension with a serological pipet gently, but thoroughly and quickly, immediately prior to aliquoting. Take care not to create bubbles during these steps. Maintain the suspension throughout the vialing process.
  - 15.7.4.1. Aliquot 1.0mL per cryovial, unless directed otherwise by protocol specific SPLI/LPC/LM.

**Note:** Evenly distribute any excess volume among all the cryovials for that PTID.

### 15.8. Overnight controlled rate freezing

- 15.8.1. Following processing and counting, complete the required steps to freeze cells immediately.
- 15.8.2. Position the selected controlled-rate freezing unit for transfers: Agilent Technologies StrataCooler®, Nalgene® Mr. Frosty™, Corning® CoolCell®. See Section 7.5 for storage and maintenance information.
- 15.8.3. Immediately transfer all cryovials in sequential global specimen ID order to the controlled-rate freezing unit.
 

For all CRFUs, Nalgene® Mr. Frosty™, Corning® CoolCell® and Agilent Technologies StrataCooler®, close the container and place it in a -80°C (-65 to -95°C for ACTG, -70 to -95°C for HVTN and HPTN) freezer, in a location that is not disturbed by repeated freezer access (i.e., away from the front or top of the freezer near the opening door/lid). Do not stack. It is recommended that all CRFUs remain in the freezer overnight.

For CryoMed® or other mechanical controlled-rate freezer, start the cooling program according to the appropriate on-site SOP. (Note for HVTN: Controlled-rate freezers are not allowed for HVTN samples).
- 15.8.4. Record the frozen date/time immediately on the PBMC worksheet. Enter the frozen date/time recorded on the worksheet into LDMS.

15.9. Document all the key elements according to network and laboratory requirements.

## 16. Quality Control

### 16.1. Cell Yields

It is important to be aware of the expected recovery for the population of participants for which the processing is performed. Cell yields can serve as internal quality control markers for each run. Yields outside the expected ranges may indicate a procedural error, reagent deterioration, cell count error, or calculation error.

**Note:** The recommendations provided below are meant to provide guidelines to help identify egregious technical errors prior to cryopreservation. These values may vary depending on the anti-coagulant used.

- 16.1.1. Expected Cell Yields for adult populations:

Population	Mononuclear Cell Yield Range (cells/mL)
Adult	(0.8 to 3.2) x 10 <sup>6</sup>

- 16.1.2. Unexpected Cell Yields



## Cross-Network PBMC Processing Standard Operating Procedure

16.1.2.1. If cell yields are outside the expected range, review dilution schemas, calculations, processing technique (especially adequate mixing of cell counting suspensions) and PTID history if available for possible causes.

16.1.2.2. Cell yields from participants living with HIV may be lower than those shown in the above table.

16.1.2.3. If cell dilution or counting errors are suspected, make a fresh dilution and recount.

16.1.3. Record all results and any problems that occur during processing and actions according to network and laboratory requirements. See Section 5 for details.

**Note for HVTN and HPTN:** Record any problems and actions on the protocol-specific HVTN PBMC Processing Worksheet, LDMS entries for aliquots, and in the cell yield comments section of the Atlas HVTN PBMC Program if appropriate. Contact the HVTN Lab Center with any concerns.

### 16.2. Cell Viability

16.2.1. Freshly isolated PBMC viability should be >95%.

16.2.2. If the fresh PBMC viability is <95%, review the results with the supervisor and document according to network and laboratory requirements.

**Note:** If samples are being prepared for the IQA PBMC Cryopreservation Proficiency Testing Program, a viable cell count is required.

## 17. PBMC Storage (Interim or On-Site)

17.1. Maintain cold chain during all transfer steps to avoid damage to the cells.

**Note for HVTN:** Ship on dry ice to the central specimen repository within 1 week of collection unless otherwise directed by the HVTN protocol specific SPLI (shipping frequency is regionally based and protocol requirement dependent). Continue to 17.2

**Note for HPTN:** Follow instructions provided in the protocol specific Laboratory Manual

**Note for ACTG:** Ship on dry ice within 4 weeks of the date of freezing unless instructed otherwise in the LPC. Continue to 17.2

17.2. Transfer PBMCs to temporary storage in a -80°C freezer.

17.2.1. Transfer the cryovials from the controlled-rate cooling system to the designated storage location at -65 to -95°C for ACTG, -70 to -95°C for HVTN and HPTN.

17.2.2. Transfer the cryovials after a minimum of 4 hours for Nalgene® Mr. Frosty™ and Corning® CoolCell® and overnight for StrataCooler® (overnight storage for all CRFUs is recommended as a standard practice to reduce risk to specimens). For CryoMed®, transfer the cryovials upon completion of the program to the -80°C freezer.

**Note: Required for HVTN and HPTN, recommended for ACTG:** Use of a dry ice transfer pan is allowed for controlled-rate freezing units only; pre-chilled tall-sided coolers are required for PBMC freezer/storage boxes. See Cross-Network Cold Chain Guidelines (Section 7, Specimen Transfer Procedures) for additional details. Make sure the cryovial freezer box and lid is covered on all sides with dry ice. Work rapidly and efficiently to minimize cryovial exposure to ambient temperatures.

**Note:** Do not store in liquid nitrogen (LN<sub>2</sub>). Store at -65 to -95°C for ACTG, -70 to -95°C for HVTN and HPTN until shipped.

**Note:** Pre-chill the dry ice shipper and use a pre-chilled tall-sided cooler during the QC and packing steps. Make sure the dry ice shipper is completely full of dry ice before sealing.

17.2.3. Contact network laboratory center personnel if samples cannot reach their destination within the network allotted temporary storage time. The network laboratory center will determine if transfer to LN<sub>2</sub> storage and shipment in LN<sub>2</sub> shippers is appropriate.

17.3. Transfer PBMCs to a LN<sub>2</sub> dewar or -150°C mechanical freezer.

**Note for HVTN:** LN<sub>2</sub> storage or the use of LN<sub>2</sub> dewars or -150°C mechanical freezers is not allowed for HVTN PBMC storage with rare exception. Labs must not transfer samples from -80°C freezers unless directed to by the HVTN LC.

17.3.1. Within 72 hours of freezing the cryovials in the controlled-rate cooling system, transfer on dry ice to the



## Cross-Network PBMC Processing Standard Operating Procedure

designated storage location in the LN<sub>2</sub> dewar or -150°C storage system.

- 17.3.2. Frozen PBMC samples are viable in LN<sub>2</sub> vapor phase indefinitely. Do NOT transfer samples from LN<sub>2</sub> or -150°C back to -80°C freezers unless directed to by network or protocol team.
- 17.3.3. Once samples have been stored in LN<sub>2</sub>, all transfers or shipments must be maintained in LN<sub>2</sub> (≤ -140°C) and shipped in an IATA-approved LN<sub>2</sub> dry shipper.

### 18. Completing Processing Documents

- 18.1. Make sure all appropriate information is documented, following good documentation practices, according to network and laboratory requirements and that all calculations are correct. See Section 5 for details.
- 18.2. Store the laboratory requisitions, PBMC Processing Worksheets and any other tracking documents according to laboratory policy.

### 19. Definitions and Acronyms

Term	Definition
ACTG	Advancing Clinical Therapeutics Globally
Centrifuge Temperature	15 to 25°C or up to 30°C, depending on climatic conditions
Clotted, Grossly	More than ¾ of the whole blood mass is clotted.
Clot, Small	Small clots noted after PBMC processing in the whole blood tube but noted on the separation tube frit after centrifugation.
CPS	Cryopreservation Solution
CSTFB	Cell Separation Tube with Frit Barrier
DGM	Density Gradient Media
FBS	Fetal Bovine Serum
HBSS	Hanks' Balanced Salt Solution
Hemolysis	A pink to red coloration of serum or plasma due to the lysis of red blood cells. Grade hemolysis according to the following scale: 1+ Pale pinkish-red color in serum or plasma, able to clearly read newspaper placed behind the blood tube 2+ Pinkish-red color in serum or plasma, newspaper is readable but not as sharp 3+ Dark pinkish-red color in serum or plasma, newspaper appears obscured. 4+ Dark red mahogany color in serum or plasma, unable to read newspaper <u>Note:</u> Lysed red blood cells give serum or plasma a colored but clear quality where red blood cell contamination gives the serum or plasma a cloudy quality.
HI-FBS	Heat Inactivated Fetal Bovine Serum
HPTN	HIV Prevention Trials Network
HVTN	HIV Vaccine Trials Network
Icteric	A green or orange tinted plasma suggesting the presence of increased bilirubin.
LDMS	Laboratory Data Management System
LM	Laboratory Manual (HPTN)
LPC	Laboratory Processing Chart (ACTG)
PBMC	Peripheral Blood Mononuclear Cells
PBS	Phosphate-buffered saline
PI	Principal Investigator
PTID/PID	Participant Identification Number
QS	Quantity Sufficient—add sufficient quantity of liquid to bring to specified volume
Room Temperature (RT)	15 to 25°C or up to 30°C, depending on climatic conditions
SPLI	Specimen Processing Laboratory Instructions (HVTN)
Usable whole blood volume (UWBV)	The measured volume of whole blood that is actually processed (The usable whole blood volume may not be equal to the capacity of the tube)
Vapor phase storage	Liquid nitrogen (LN <sub>2</sub> ) vapor-phase storage is the space in the storage tank that is above the LN <sub>2</sub> liquid at the bottom of the tank.
WDR	Wash Diluent Reagent (HBSS, PBS)



### 20. References

- 20.1. Bull M., Lee B., Stucky J., Chiu Y.L., Rubin A., Horton H., and McElrath MJ. Defining blood processing parameters for optimal detection of cryopreserved antigen-specific responses for HIV vaccine trials. *J. Immunol. Methods* 322:57-69 (2007).
- 20.2. CHAVI SOP for PBMC Isolation and Cryopreservation, CHAVI-A0001, v5, Nov 3 2008.
- 20.3. Cox J.H., DeSouza M., Ratto-Kim S., Ferrari G., Weinhold K.J., and Birx B.L. Cellular Immune assays for evaluation of Vaccine efficacy in developing countries. *Manual of Clinical laboratory Immunology*. Rose N.R., Hamilton R.G., Detrick B. Eds. (6th ed.) p.301-315 (2002).
- 20.4. Islam B., Lindbert A., and Christensen B. Peripheral blood cells preparation influences the level of expression of leukocyte cell surface markers as assessed with quantitative multicolor flow cytometry. *Cytometry* 22:128-134 (1995).
- 20.5. Immunovirology Research Network (IVRN) Laboratory Manual: Separation and storage of serum, plasma and PBMCs. IVRN. Dec 12 2007.
- 20.6. Kierstead L.S., Dubey S., Meyer B., Tobery T.W., Mogg R., Fernandez V.R., Long R., Guan L., Gaunt C., Collins K., Sykes K.J., Mehrotra B.V., Chirmule N., Shiver J.W., and Casimiro B.R. Enhanced rates and magnitude of immune responses detected against an HIV vaccine: effect of using an optimized process for isolating PBMC. *AIDS Res Hum Retroviruses* 23:86-92 (2007).
- 20.7. Shearer WT, Rosenblatt HM, Gelman RS, Oyomopito R, Plaeger S, Stiehm ER, Wara DW, Douglas SD, Luzuriaga K, McFarland EJ, Yogev R, Rathore MH, Levy W, Graham BL, Spector SA; Pediatric AIDS Clinical Trials Group. Lymphocyte subsets in healthy children from birth through 18 years of age: the Pediatric AIDS Clinical Trials Group P1009 study. *J Allergy Clin Immunol.* 112(5):973-80 (2003).
- 20.8. Sigma-Aldrich Accuspin™ System-Histopaque®-1077, procedure number A6929/A7054/A0561, Dated 2003-09.
- 20.9. Weinberg A., Betensky R., Zhang L., and Ray G. Effect of shipment, storage, anticoagulant, and cell separation on lymphocyte proliferation assays for human immunodeficiency virus-infected patients. *Clin. Diagn. Lab. Immunol.* 5:804-807 (1998).
- 20.10. Weinberg A, Song LY, Wilkening CL, Fenton T, Hural J, Louzao R, Ferrari G, Etter PE, Berrong M, Canniff JD, Carter D, Defawe OD, Garcia A, Garrelts TL, Gelman R, Lambrecht LK, Pahwa S, Pilakka-Kanthikeel S, Shugarts DL, and Tustin NB. Optimization of storage and shipment of cryopreserved peripheral blood mononuclear cells from HIV-infected and uninfected individuals for ELISPOT assays. *J Immunol Methods.* 363(1):42-50 (2010).

### 21. Appendices

- 21.1. Appendix A: Generic HVTN-HPTN PBMC Processing Worksheet  
*Note:* Appendix A is also provided as downloadable forms on the HANC public website at <https://www.hanc.info/resources/sops-guidelines-resources/laboratory/cross-network-pbmc-processing-sop.html>
- 21.2. Appendix B: ACTG PBMC Processing Worksheet
- 21.3. Appendix C: Example Nalgene® Mr. Frosty Isopropanol Change Log
- 21.4. Appendix D: Troubleshooting: Recovery of PBMC in the Absence of a Defined PBMC Band after Density Gradient Centrifugation
- 21.5. Appendix E: Pooling Buffy Coat Layers for Density Gradient Media PBMC isolation
- 21.6. Appendix F: Cross-Network PBMC SOP Quick Guide—CSTFB
- 21.7. Appendix G: Cross-Network PBMC SOP Quick Guide—Manual Overlay Method
- 21.8. Appendix H: Example Reagents
- 21.9. Appendix I: Revision History



## PBMC Specimen Processing Standard Operating Procedure

### Appendix A: Generic HVTN-HPTN PBMC Processing Worksheet

Note: For HPTN and HVTN, use the protocol-specific PBMC Processing Worksheet found in the protocol specific Specimen Processing Laboratory Instructions (SPLI) or Laboratory Manual unless otherwise directed. Complete all fields by hand, using a pen.

Specimen Processing Laboratory:	Protocol:
Participant ID (PTID/PID):	Visit Number: Visit Type:
Collection Date:	Collection Time:
Processing Start Date:	Processing Start Time: Processed By (Initials):

Reagents	Manufacturer	Lot Number	Expiration Date
DMSO			
FBS			
WDR: HBSS or PBS (circle one)			
Cell Separation Tube (frit)			
Density Gradient Media			
	Volume in mL (record as X.Y)		Expiration Date
CPS	CPS	DMSO	FBS
			1 working day (<18hrs)
<b>Data to be Captured During Processing</b>			<b>Sample</b>
Sample tube type (circle one or record "other" tube type)			ACD / HEP / EDT Other: _____
Blood condition (circle one or more; add comments on reverse as needed)			SAT/ HEM / CLT
Measured usable whole blood volume (to the nearest 0.1mL)			mL
Indicate processing method (circle one)			CSTFB / overlay / underlay
Counting Method: Name of specific instrument or manual count (record in field to right)			
Counting resuspension volume of HBSS (or other WDR) (V) (record as X.Y)			mL
Cell count average concentration (C)			x 10 <sup>6</sup> cells/mL
Total cell number (T) = C x V			x 10 <sup>6</sup> cells
Calculate cell yield/mL of whole blood (QC check)= (T/Usable Whole Blood Volume)			x 10 <sup>6</sup> cells/mL
Calculate estimated CPS resuspension vol. (V1)=(T/15x10 <sup>6</sup> cells)(1mL)			mL
Calculate final CPS resuspension volume (Vf), (V1 rounded DOWN to nearest whole (X.0) mL)			mL
Calculate actual number of cells per vial <b>N2 = (T/Vf) x V2; (V2=1 mL).</b>			x 10 <sup>6</sup> cells/vial
Print and QC LDMS Label content/barcodes (initials of person (s) performing QC)			
Frozen Date and Time (ddMMMyyyy /HH:MM) (Explain in comments section if not within <b>4 hours</b> of processing start time)			
Number of Cryovials actually frozen <b>Note:</b> Should be equal to final CPS resuspension volume for 1mL aliquots (Vf).			
Complete remaining LDMS entries including total cell count & frozen time (Initials)			



## PBMC Specimen Processing Standard Operating Procedure

### Appendix A: Generic HVTN-HPTN PBMC Processing Worksheet Page 2 of 2

**Note:** For HPTN and HVTN, use the protocol-specific PBMC Processing Worksheet found in the protocol specific Specimen Processing Laboratory Instructions (SPLI) or Laboratory Manual unless otherwise directed. Complete all fields by hand, using a pen.

Specimen Processing Laboratory:

PTID/PID:

Transfer of Cryovials to Freezer Storage Box	
Person who transferred cryovials to storage box locations assigned by LDMS	
Date (ddMMMyyyy)/time cryovials were transferred from controlled-rate freezing device to storage box. (Sample must be maintained at -80°C during transfer)	
Initial (Primary) Review (Initials/Date)	
Final (Secondary) Review (Initials/Date)	

Hemacytometer Counts	Total Count	Viable Cells	Non-Viable
Square #1 (cells/mm <sup>2</sup> )			
Square #2 (cells/mm <sup>2</sup> )			
Square #3 (cells/mm <sup>2</sup> )			
Square #4 (cells/mm <sup>2</sup> )			
Average Cell Count per Square (cells/mm <sup>2</sup> )			
PBMC Dilution Factor (1:DF*)			
Hemacytometer Factor for cells/mL	10 <sup>4</sup>	10 <sup>4</sup>	10 <sup>4</sup>
Cell count concentration (C) = (Average Cells/mm <sup>2</sup> )(DF)(10 <sup>4</sup> ); convert to 10 <sup>6</sup> cells/mL	Not applicable	x 10 <sup>6</sup> cells/mL	Not applicable
% viability = (Viable cells 4 squares/total cells 4 squares) (100)	Not applicable		Not applicable

\***Note:** Dilution Factor (DF) = (parts cells + parts dilution fluid)/ parts cells

Automated Cell Counts (10 <sup>3</sup> /μl=10 <sup>6</sup> /mL)	Count #1
Cell Count (C) as cells x 10 <sup>6</sup> /mL	
PBMC Dilution Factor (1:DF**)	
Cell Concentration = (C)(DF)	x 10 <sup>6</sup> cells/mL
% viability (if applicable)	

\*\***Note:** Dilutions for automated counters are extremely rare. If performing direct counts, enter a 1 in the DF box and complete the column.

Comments, protocol deviations, and additional information not captured elsewhere in this worksheet:



## PBMC Specimen Processing Standard Operating Procedure

### Appendix B: ACTG PBMC Processing Worksheet v8.0 (Page 1 of 2)

**Note:** The fields in this worksheet must be filled out by hand, using a pen.

Refer to Protocol LPC for N1 and A (for IQA certification/testing refer to current program description).

Specimen Processing Laboratory:	Submission type (circle one): IQA or Protocol	
Protocol Number (N/A if IQA):	N1:	A*:
Participant ID (PTID/PID):	Visit Number:	Visit Type:
Collection Date:	Collection Time:	
Processing Start Date:	Processing Start Time:	Processed By (Initials):

Reagents	Visual QC (yes/no)	Manufacturer	Lot Number	Expiration Date
DMSO				
FBS				
WDR: HBSS or PBS (circle one)				
Cell Separation Tube (frit)				
Density Gradient Media				
	Volume in mL (record as X.Y)			Expiration Date
CPS		CPS	DMSO	FBS
				1 working day (<18hrs)
<b>Data to be Captured During Processing</b>				<b>Sample</b>
Sample tube type (circle one or record "other" tube type)				ACD / HEP / EDT Other: _____
Blood condition (circle one or more; add comments on reverse as needed)				SAT/ HEM / CLT Other: _____
Measured usable whole blood volume ( <b>WBV</b> ) (to the nearest 0.1mL)				mL
Measured plasma volume removed & replaced with equal volume of WDR (to the nearest 0.1mL)				
Indicate processing method (circle one)				CSTFB / overlay / underlay
Counting Method: Name of specific instrument or manual count (record in field to right)				
Counting re-suspension volume of WDR) ( <b>V</b> ) = WBV X 0.20 (rounded to the nearest whole (X.0)mL)				mL
Cell count average concentration ( <b>C</b> )				x 10 <sup>6</sup> cells/mL
Total cell number ( <b>T</b> ) = <b>C x V</b>				x 10 <sup>6</sup> cells
Calculate cell yield/mL of whole blood. (QC check)= (T/Usable Whole Blood Volume)				x 10 <sup>6</sup> cells/mL
If <b>T/A ≥ N1</b> ; then CPS re-suspension vol ( <b>V1</b> ) = <b>A*</b> If <b>T/A &lt; N1</b> ; then calculate estimated CPS re-suspension vol. ( <b>V1</b> )=( <b>T/N1x10<sup>6</sup> cells</b> )(1mL)				mL
Calculate final CPS re-suspension volume ( <b>V<sub>f</sub></b> ), (V1 rounded DOWN to nearest whole (X.0) mL)				mL
Calculate actual number of cells per vial. <b>N2</b> = ( <b>T/V<sub>f</sub></b> ) x <b>V2</b> ; (V2=1 mL). <b>Note:</b> Do not store more than 50M cells per vial				x 10 <sup>6</sup> cells/vial
Number of Cryovials actually frozen <b>Note:</b> Should be equal to final CPS re-suspension volume for 1mL aliquots ( <b>V<sub>f</sub></b> ) and ≤ ( <b>A</b> )*				
Print and QC LDMS Label content/barcodes (initials of person (s) performing QC)				
Frozen Date and Time (ddMMMyyyy /HH:MM) (Explain in comments section if not within <b>4 hours</b> of processing start time)				
Complete remaining LDMS entries including total cell count & frozen time (Initials)				

**Note:** A\* = The maximum number of aliquots required according to the protocol-specific Laboratory Processing Chart (LPC). Do not store more than this number of aliquots. For IMPAACT please follow protocol defined requirements.



## PBMC Specimen Processing Standard Operating Procedure

### Appendix B: ACTG PBMC Processing Worksheet v8.0 (Page 2 of 2)

**Note:** The fields in this worksheet must be filled out by hand, using a pen.

Specimen Processing Laboratory:

PTID/PID:

Transfer of Cryovials to Freezer Storage Box	
Person who transferred cryovials to storage box locations assigned by LDMS	
Date (ddMMMyyyy)/time cryovials were transferred from controlled-rate freezing device to storage box. (Sample must be maintained at -80°C during transfer)	
Initial (Primary) Review (Initials/Date)	
Final (Secondary) Review (Initials/Date)	

Hemocytometer Counts	Total Count	Viable Cells	Non-Viable
Square #1 (cells/mm <sup>2</sup> )			
Square #2 (cells/mm <sup>2</sup> )			
Square #3 (cells/mm <sup>2</sup> )			
Square #4 (cells/mm <sup>2</sup> )			
Average Cell Count per Square (cells/mm <sup>2</sup> )			
PBMC Dilution Factor (1:DF*)			
Hemocytometer Factor for cells/mL	10 <sup>4</sup>	10 <sup>4</sup>	10 <sup>4</sup>
Cell count concentration (C) = (Average Cells/mm <sup>2</sup> )(DF)(10 <sup>4</sup> ); convert to 10 <sup>6</sup> cells/mL	Not applicable	x 10 <sup>6</sup> cells/mL	Not applicable
% viability = (Viable cells 4 squares/total cells 4 squares) (100)	Not applicable		Not applicable

Automated Cell Counts (10 <sup>3</sup> /μl=10 <sup>6</sup> /mL)	Count #1
Cell Count (C) as cells x 10 <sup>6</sup> /mL	
PBMC Dilution Factor (1:DF**)	
Cell Concentration = (C)(DF)	x 10 <sup>6</sup> cells/mL
% viability (if applicable)	

**\*\*Note:** Dilution Factor (DF) = (parts cells + parts dilution fluid)/ parts cells

**\*\*\*Note:** Dilutions for automated counters are extremely rare. If performing direct counts, enter a 1 in the DF box and complete the column.

Comments, protocol deviations, and additional information not captured elsewhere in this worksheet:



**Appendix D: Troubleshooting: Recovery of PBMC in the Absence of a Defined PBMC Band after Density Gradient Centrifugation**

**D.1. Background:** If something has gone wrong during the density gradient centrifugation of the blood, the density gradient media and plasma layer will not separate cleanly and you may not see a PBMC layer. Do not panic. Partial recovery of the PBMC can be achieved with additional steps.

**D.2 Identify the problem:**

D.2.1 Remove tubes from centrifuge and transfer to a rack.

D.2.2 Try to identify why there isn't a clear PBMC layer. Possible causes are listed below:

- The tube was dropped or bumped.
- The brake was left on.
- The centrifugation speed was too high. Verify that the rpm setting was correct for the procedure used (CSTFB or manual density gradient cell separation) by checking the RCF/rpm chart for the rotor. Some centrifuges require that the settings on the centrifuge match the type of bucket used. If the settings are not correct then the centrifuge may miscalculate its speed.
- The centrifuge stopped due to a discontinuity in the electricity supply.
- The frit dislodged. (This is often due to a centrifugation speed that was too high, but occasionally there is a defective tube in the batch.)
- The centrifuge was misbalanced.
- The donor has low lymphocyte, white blood cell or hematocrit counts.

**D.3 Of the above causes, the first five causes are easily fixed. If the cause is due to a misbalanced centrifuge, determine why the centrifuge was misbalanced. Check the following:**

D.3.1 Check that the tubes were balanced.

D.3.2 Check that the centrifuge buckets were balanced.

D.3.3 Check that the centrifuge arms and buckets were properly greased and oiled

Note: If ever in doubt about a centrifuge, use another one.

**D.4 Assuming the problem is fixed, re-centrifuge the samples as follows:**

D.4.1 Reagents:

- Density gradient media
- 50mL conical centrifuge tubes
- Pipets

D.4.2 Method:

Note: Density gradient media is toxic to cells so work efficiently

D.4.2.1 Add 15mL of density gradient media to sterile 50 mL tubes (not CSTFB).

D.4.2.2 Allow the density gradient media to warm to room temperature (15 to 25°C or up to 30°C, depending on climatic conditions) while working with the sample.

- D.4.2.3 For each mixed tube, label 50mL tubes with subject PTID. Use a pipet to slowly remove the contents of the mixed sample from the separation or CSTFB. (Typically, the CSTFB frit will have dislodged.)
- D.4.2.4 Transfer up to 30mL of the mixed sample to the tube containing density gradient media.
- D.4.2.5 Repeat this for all mixed samples.
- D.4.2.6 Place the tubes into the centrifuge, checking that the tubes are balanced.
- D.4.2.7 Centrifuge for 30 to 40 minutes at 400 x g with the Brake OFF at room temperature (15 to 25°C or up to 30°C, depending on climatic conditions).
- D.4.2.8 A PBMC layer should now be visible. (Often some cells will have been lost, so the layer could be thin.)
- D.4.2.9 Carefully transfer the PBMC layer to a 50mL conical centrifuge tube labeled with the PTID identifier. Use one new tube for every density gradient media tube.
- D.4.2.10 Re-cap the density gradient media tube.
- D.4.2.11 Return to Section 15 of the main protocol.

**Note:** In the “Comments and Protocol Deviations” section of the **PBMC Processing Worksheet**, record the details of the deviation from the SOP (i.e. that steps from “Appendix D” were taken to recover PBMC due to the absence of a defined PBMC band after density gradient centrifugation). In addition, note how long the re-centrifugation took in order to provide an estimate of how long cells were in density gradient media.


### **Appendix E: Pooling Buffy Coat Layers for Density Gradient Media PBMC Isolation**

This procedure can be used when isolating PBMCs from multiple tubes of blood of the same PTID- anticoagulant combination. This procedure allows one to consolidate the buffy coat layers to reduce the use of reagents and consumables, increase recovery and decrease contamination.

The buffy coat is the fraction of whole anticoagulated blood that contains white blood cells (WBCs) and platelets and occurs after centrifugation at the interface of plasma and red blood cell layers. Most WBCs are found in the buffy coat layer with only a very small fraction (<1 million total) remain in the red cell pack after buffy coat harvest. The buffy coat layer is harvested with a small fraction of plasma and red blood cells (approximately 1.5mL) and then diluted prior to overlaying on a gradient medium for lymphocyte separation.

Procedure:

- E1. Make sure that you have completed the steps in Sections 14.4.1 through 14.4.2.
- E2. Centrifuge whole blood at 200 to 400 x g for 10 minutes.
- E3. Harvest plasma (and save as needed - see Section 14.3.4 through 14.3.7) from each tube to within about 5mm from the buffy coat layer (which is obvious in most cases unless the patient is severely neutropenic/lymphopenic).
- E4. Determine the capacity and number of conical centrifuge tubes that will be needed for each PTID- anticoagulant combination. Do not pool samples from different PTIDs/anticoagulants. In general:
  - Buffy coats from two 10mL blood collection tubes can be combined into one 15mL conical centrifuge tube.
  - Buffy coats from up to six 10mL blood collection tubes can be combined into one 50mL conical centrifuge tube.
- E5. Label each conical centrifuge tube with the PTID.
- E6. Add WDR to each sterile conical centrifuge tube.



Conical Centrifuge Tube Capacity (mL)	WDR volume (mL)
15	3
50	10-15

- E7. Hold the plasma depleted tube (which now contains a small amount of residual plasma and packed cells) at about a 30° angle.
- E8. Use a sterile, 2.5mL, wide bore, disposable polypropylene pipet to harvest the buffy coat. Aspirate the buffy coat by moving down the low end of the tube. Slowly draw in the plasma followed by the buffy coat which will “slide” down the packed red cell layer (about 1.5mL of aspirate). Transfer the buffy coat to the WDR-containing tube, rinsing the pipet 2 to 3 times with WDR/cell suspension.
- E9. Harvest and pool the buffy coats from the remaining tube(s) for that PTID-anticoagulant combination.
- E10. QS the WDR/cell suspension with additional WDR to the desired volume for performing the density gradient cell separation. Gently mix the buffy coat pool 3 to 4 times with a pipet.
- E11. Continue with density gradient cell separation at step in Section 14.5. For 14.5, “diluted blood” means “diluted buffy coat.”



## PBMC Specimen Processing Standard Operating Procedure

### Appendix F: Example Reagents and Supplies

Note: All reagents must be purchased sterile, and the use of aseptic technique is required.

Reagent/Supply	Example(s)	Optional/Required
Dry CSTFB	<ul style="list-style-type: none"> <li>• Accuspin™ separation tubes</li> <li>• Leucosep® separation tubes</li> </ul>	Optional ( <b>Note for HVTN:</b> Required)
Pre-filled cell separation tubes with frit barriers (CSTFB) with 1.077 density gradient media	<ul style="list-style-type: none"> <li>• Accuspin™ System Histopaque®-1077</li> </ul>	Optional ( <b>Note for HVTN:</b> Not allowed without network approval)
1.077 Density Gradient Media	<ul style="list-style-type: none"> <li>• Ficoll-Paque PLUS and PREMIUM</li> <li>• Lymphoprep™</li> <li>• Lymphocyte Separation Media – LSM™</li> </ul>	Optional
Dimethyl sulfoxide (DMSO), cell culture grade	<ul style="list-style-type: none"> <li>• Hybrimax, Sigma-Aldrich cat# D2650, endotoxin tested, hybridoma tested</li> <li>• Or equivalent product</li> </ul>	Required
Fetal Bovine Serum (FBS)		<p><b>ACTG:</b> Refer to <a href="http://www.actg-impact-lc.org">www.actg-impact-lc.org</a> under resources &gt; documents for current FBS ordering information and required lots.</p> <p><b>HPTN:</b> Refer to information about current IQA-validated lots.</p> <p><b>HVTN (and certain cross network protocols with HVTN):</b> HVTN-approved FBS is provided to labs by the network as heat inactivated and must not be purchased outside of the HVTN supply chain/process.</p>
Cryovials	<ul style="list-style-type: none"> <li>• Nunc CryoTubes™, internal thread, polypropylene (PP) tubes and screw cap #377267</li> <li>• Greiner Cryotubes, internal thread, natural screw cap, polypropylene (PP), round bottomed, writing area, starfoot, sterile #122263</li> <li>• Corning® 2mL internal thread polypropylene cryogenic vial, self-standing with round bottom #430488</li> </ul>	<p>Nunc Preferred / internal thread required for all networks.</p> <p><b>Note for HVTN:</b> Nunc CryoTubes™ #377267 are required for HVTN network protocols. Any substitutions must be approved by HVTN before being purchased by laboratories.</p>
Cryogenic labels	<ul style="list-style-type: none"> <li>• Cryo-Tags® and Cryo-Babies® Brady B461 or B490</li> <li>• Shamrock freezer labels.</li> </ul>	Optional
Marking pens	<ul style="list-style-type: none"> <li>• Fisherband* Marking Pens #13-379</li> <li>• Nalgene® Lab Pen/Lab Marker #6310/#6311</li> </ul>	Optional



## PBMC Specimen Processing Standard Operating Procedure

### Appendix G: PBMC SOP Quick Guide—CSTFB

Use of a **PBMC Processing Worksheet** and the LDMS is **required for all networks** (see Section 5 for details). Before using this quick guide for the first time, be sure to review the complete PBMC SOP for important notes and details, and network-specific guidelines.

Steps	Reference to SOP
1. Prepare and chill the CPS.	11.2
2. Prepare whole blood samples, reagents, and supplies.	13.2
3. If plasma aliquots <b>are</b> required per protocol instructions: <ol style="list-style-type: none"> <li>Centrifuge the whole blood at 200 to 400 x g for 10 minutes.</li> <li>Mark the total blood volume at the meniscus then transfer plasma to a labeled 15 or 50mL conical centrifuge tube for further processing (800 to 1200 x g for 10 minutes, brake optional)</li> <li>Add sufficient quantity of WDR to bring blood back to its original whole blood volume, mix gently and continue PBMC processing.</li> </ol>	13.3
4. Add 5mL of WDR to each labeled CSTFB and 25mL of WDR to each labeled corresponding 50mL conical wash tube. ( <b>Note:</b> Can be performed earlier as part of setup [step 2]).	13.4
5. Transfer 15 to 20mL (12-22 allowed) of blood into the labeled CSTFBs. <ol style="list-style-type: none"> <li>Track measured volumes carefully. Record measured UWBV accurate to nearest 0.1mL.</li> </ol>	
6. Add WDR tube rinse and final WDR to CSTFB up to 30mL (WDR + Whole Blood).	
7. Centrifuge at 800 to 1000 x g for 15 minutes at 15 to 30°C with the <u>Brake OFF/set to zero</u> .	13.5
8. Inspect the tubes for possible problems.	
9. Harvest each CSTFB buffy coat into a labeled corresponding single labeled 50mL conical centrifuge tube pre-filled with 25mL of WDR.	
10. Add WDR to QS to a total volume of 45mL and mix gently.	15.1
11. Wash #1—centrifuge at 200 to 400 x g for 10 minutes at 15 to 30°C, brake optional.	
12. Check for the cell pellets! Document unexpected observations.	
13. Gently remove the supernatant without disturbing the cell pellet.	
14. Resuspend the cell pellet in small amount of WDR making a homogenous cell suspension.	15.2
15. Combine up to 4 pellet suspensions into one 50mL conical centrifuge tube.	
16. Add WDR tube rinse and final WDR of 45mL to cell tube.	
17. Wash #2—Centrifuge at 200 to 400 x g for 10 minutes at 15 to 30°C, brake optional.	
18. Check for the cell pellets! Document unexpected observations.	
19. Gently remove the supernatant without disturbing the cell pellet.	
20. Calculate the WDR counting resuspension volume (V).	15.3
21. Combine cell pellets into one tube using resuspension volume WDR. This is the volume on which the cell count is based.	
22. Count and calculate the total number of cells	
23. Calculate the cell yield in cells/mL of usable whole blood.	
24. Calculate final CPS resuspension volume. Check calculations.	15.4
25. Complete the printing, labeling and QC of cryovials PRIOR to the final centrifugation.	15.5
26. Centrifuge at 200 to 400 x g for 10 minutes at 15 to 30°C, brake optional.	15.6
27. Gently remove the supernatant without disturbing the cell pellet.	15.7
28. Gently resuspend the pellet in <b>cold</b> CPS ( $V_f$ ) while swirling the tube for even distribution. Gently make CPS-cell aliquots.	
29. Immediately ( $\leq$ 10 minutes from addition of CPS to sample) transfer all cryovials to the controlled rate freezing unit and place in freezer.	15.8
30. After the appropriate time period, transfer cryovials to the onsite storage equipment and ship within the time period designated by the network.	17
31. Complete and review the <b>PBMC Processing Worksheet</b> and data entries as directed by network.	18.1



## PBMC Specimen Processing Standard Operating Procedure

### Appendix H: PBMC SOP Quick Guide—Manual Overlay

Use of a **PBMC Processing Worksheet** and the LDMS is **required for all networks** (see Section 5 for details). Before using this quick guide for the first time, be sure to review the complete PBMC SOP for important notes and details, and network-specific guidelines.

Steps (Quantities for smaller sample volumes are <i>italicized</i> .)	Reference to SOP
1. Prepare and chill the CPS.	11.2
2. Prepare whole blood samples, reagents, and supplies.	14.2
3. If plasma aliquots <b>are</b> required per protocol instructions: <ol style="list-style-type: none"> <li>Centrifuge the whole blood at 200 to 400 x g for 10 minutes.</li> <li>Mark the total blood volume at the meniscus then transfer plasma to a 15 or 50mL conical centrifuge tube for further processing (800 to 1200 x g for 10 minutes, brake optional).</li> <li>Add sufficient quantity of WDR to bring blood back to its original whole blood volume, mix gently and continue PBMC processing.</li> </ol>	14.3
4. Transfer whole blood to sterile, 50mL ( <i>15mL</i> ) conical centrifuge tube and dilute with WDR as needed.	14.4
5. Carefully and slowly overlay blood on top of the density gradient medium. (Underlay Method is an approved alternative, with the exception of HVTN protocols.)	
6. Centrifuge at 400-800 x g for 15-30 minutes with the <u>Brake OFF/set to zero</u> .	14.5
7. Check each conical centrifuge tube for possible problems.	
8. Harvest each buffy coat into a corresponding single, 50mL ( <i>15mL</i> ) conical centrifuge tube.	
9. Add WDR to QS to a total volume of 45mL ( <i>10mL</i> ) and mix gently.	15.1
10. Wash #1—centrifuge at 200 to 400 x g for 10 minutes at 15 to 30°C, brake optional.	
11. Check for the cell pellets!	
12. Gently remove the supernatant without disturbing the cell pellet.	
13. Resuspend the cell pellet in small amount of WDR making a homogenous cell suspension.	15.2
14. Combine up to 4 pellet suspensions into one 50mL conical centrifuge tube ( <i>2 into 15mL tube</i> ).	
15. Add WDR tube rinse and final WDR up to 45mL ( <i>10mL</i> ) to cell tube.	
16. Wash #2—Centrifuge at 200 to 400 x g for 10 minutes at 15 to 30°C, brake optional.	
17. Check for the cell pellets!	
18. Gently remove the supernatant without disturbing the cell pellet.	
19. Calculate the WDR counting resuspension volume (V).	15.3
20. Combine cell pellets into one tube using resuspension volume WDR. This is the volume on which the cell count is based.	
21. Count and calculate the total number of cells	
22. Calculate the cell yield in cells/mL of usable whole blood.	
23. Calculate final CPS resuspension volume. Check calculations.	15.4
24. Complete the printing, labeling and QC of cryovials PRIOR to the final centrifugation.	15.5
25. Centrifuge at 200 to 400 x g for 10 minutes at 15 to 30°C, brake optional.	15.6
26. Gently remove the supernatant without disturbing the cell pellet.	15.7
27. Gently resuspend the pellet in <b>cold</b> CPS ( $V_f$ ) while swirling the tube for even distribution. Working on wet ice is recommended.	
28. Gently make CPS-cell aliquots.	
29. Immediately ( $\leq$ 10 minutes from addition of CPS to sample) transfer all cryovials to the controlled rate freezing unit and place in freezer.	15.8
30. After the appropriate time period, transfer cryovials to the onsite storage equipment and ship within the time period designated by the network.	17
31. Complete and review the <b>PBMC Processing Worksheet</b> and data entries as directed by network.	18.1



## PBMC Specimen Processing Standard Operating Procedure

### Appendix I: Revision History from Version 7.0 to 8.0

Version Effective Date (dd/mmm/yy)	Section(s)	Revision
8.0 14Jun2026	Cover Page	Version, effective date, superseded date, and appendix reference updated.
	Table of Contents	TOC added with new page numbers for all sections and appendices.
	5	Network-specific worksheet requirements clarified; ACTG requirement added; LPC reference removed; key elements tracking table updated.
	6	Minor wording corrections in clotted specimen and low cell yield sections
	10	Appendix cross-references updated consequential to appendix re-lettering
	11	CPS Preparation restructured: split into Method 1 (HVTN/HPTN) and Method 2 (ACTG) with updated formulas, examples, and steps.
	15	CPS resuspension steps reordered and clarified. Appendix cross-references updated.
	Appendices	New Appendix B added (ACTG PBMC Processing Worksheet). All appendices re-lettered. Appendix A retitled.
	Appendix I (Revision History)	Renamed from Appendix H; updated to reflect v8.0
7.0 19Aug2024	All	Revised HANC logo added in header
	All	Reference to MTN removed
	All	Reference to IMPAACT removed
	All	Comprehensive update of all sections to align with current guidelines, protocols, and practices.
	Approvals	MTN authorization removed
	Approvals	IMPAACT authorization removed
	Approvals	Kathryn Dougherty replaced John Hural for HVTN authorization
	8.1.5	Requirement for internally threaded cryovials for PBMC storage
	15.4	Vialing method aligned across ACTG, HPTN, and HVTN
6.0 26 Apr 2018	Approvals	Grace Aldrovandi replaced Bob Coombs for ACTG authorization. John Hural replaced Constance Ducar for HVTN authorization. Edward Livant replaced Charlene Dezzutti for MTN authorization.
	8.1.4	Additional requirements captured in October 7, 2016 memo for ACTG and IMPAACT labs only added. Additional cryovial-related requirements for all networks also added.
	18.2.1	Additional guidelines related to freezer set point temperatures added.
	Appendix D	Changed "The majority of WBCs..." to "Most WBCs..."
	Appendix G	Added additional information to the Cryovial section related to use of the SARSTEDT Screw cap micro tube.
5.2 22 Sept 2014	5.1.3	Changed "The lab may use the <b>HVTN PBMC Processing Worksheet</b> , or modify it as appropriate for that laboratory's procedures." to "The lab may use the <b>HVTN PBMC Processing Worksheet</b> , modified to follow corresponding network requirements and appropriate for the laboratory's procedures."
5.1 30 July 2014	5.1.3	Guidelines for tracking PBMC processing chart-: Total cell number : "(optional for HVTN)" was added next to N
	16.4.5	Note was omitted since there is no frit in the conical tubes when doing manual overlay or underlay
	16.4.6	References for Overlay Method was changed to 16.4.6.1 and Underlay Method to 16.4.6.2
	18.1	Added storage /transfer time guidelines for HPTN, IMPAACT, and MTN.
	14, 18.1, 18.3, 18.3.1	Changed "LN2/-150°C mechanical Freezer " to "LN2 dewar or -150°C mechanical freezer"



## PBMC Specimen Processing Standard Operating Procedure

	18.3	Simplified language to PBMCs stored in LN2 dewar or -150°C mechanical freezer and excluded “longer than 4 weeks” stipulation.
	18.3.1-18.3.2	Changed required transfer time guideline from “next working day” to “Within 72 hours”
	18.3.1	Changed “LN2/-150°C” to “LN2 or -150°C”
	22, 24.2	RPMP option was deleted
	Appendix E, F	Changed Step 1 SOP Reference from “11.3” to “11.2”
	Appendix E	Changed Step 31 SOP Reference from “18 or 19” to “18”
	Appendix E	Changed Step 32 SOP Reference from “19.2” to “19.1”
	Appendix E	Changed Step 32 statement to “Complete the <b>PBMC Processing Worksheet</b> as directed by network.”
	Appendix F	Steps 9-12: changed “16.1” to “17.1”
	Appendix F	Steps 13-18: changed “16.2” to “17.2”
	Appendix F	Steps 19-22: changed “16.3” to “17.3”
	Appendix F	Changed Step 30 SOP Reference from “18 or 19” to “18”
	Appendix F	Changed Step 31 SOP Reference from “19.2” to “19.1”
	Appendix F	Changed Step 31 statement to “Complete the <b>PBMC Processing Worksheet</b> as directed by network.”
5.0 01 May 2014	Approvals	Grace Aldrovandi replaced Susan Fiscus for IMPAACT Authorization
	5.1.3	Guidelines for Tracking PBMC Processing Chart : Instructions: “L = Tracking in the LDMS is required by the LDMS” was changed to “L= Required field in LDMS for network specimens”
	5.1.3	Guidelines for tracking PBMC processing table-: “LDMS Specimen Number” was changed to “LDMS Global Specimen ID”
	5.1.3	Cells that were filled in Gray to indicate that information is not needed is changed to black.
	7.1.8	Added HPTN and MTN
	10.2	Alternative for using RPMP as a substitute is omitted
	14	Formatting changes
	18 and 19	Combined interim and on-site storage instructions from two sections into one, Section 18.
	19	Completing processing documents language that was repeated in Section 18 and Section 19 is separated into its own section.
Appendix H	Deleted other Version history changes, maintaining only the current version changes appropriate to this document.	

## Certificate Of Completion

Envelope Id: D9AFB5F5-340A-883C-81F5-98BC67FD0195  
 Subject: Complete with Docusign: Cross-Network PBMC Processing SOP v8.0\_12Jun2026.pdf  
 Source Envelope:  
 Document Pages: 39  
 Certificate Pages: 5  
 AutoNav: Enabled  
 Envelopeld Stamping: Enabled  
 Time Zone: (UTC-08:00) Pacific Time (US & Canada)

Status: Completed  
 Envelope Originator:  
 Russell Campbell  
 1100 Fairview Avenue North  
 Seattle, WA 98109  
 rcampbel@fredhutch.org  
 IP Address: 140.107.167.67


## Record Tracking

Status: Original  
 6/12/2026 12:17:56 PM  
 Holder: Russell Campbell  
 rcampbel@fredhutch.org  
 Location: DocuSign

## Signer Events

Estelle Piowar-Manning  
 epiwowa@jhmi.edu  
 Security Level: Email, Account Authentication  
 (None)

## Signature

DocuSigned by:  
  
 731B45B052A74D8...


## Timestamp

Sent: 6/12/2026 1:03:41 PM  
 Viewed: 6/12/2026 1:55:55 PM  
 Signed: 6/12/2026 1:56:26 PM

Signature Adoption: Pre-selected Style  
 Using IP Address: 128.220.159.182

**Electronic Record and Signature Disclosure:**  
 Accepted: 6/12/2026 1:55:55 PM  
 ID: d87520b1-6ef9-4f51-91a6-69e6e498e1f6

Grace Aldrovandi  
 gracea@mac.com  
 Professor  
 Security Level: Email, Account Authentication  
 (None)

DocuSigned by:  
  
 6BE9A0BACDFE4FA...

Sent: 6/12/2026 1:03:40 PM  
 Viewed: 6/12/2026 1:09:56 PM  
 Signed: 6/12/2026 1:10:31 PM

Signature Adoption: Pre-selected Style  
 Using IP Address: 149.142.103.136  
 Signed using mobile

**Electronic Record and Signature Disclosure:**  
 Accepted: 6/12/2026 1:09:56 PM  
 ID: 0f089057-907f-4b57-924c-ecbcb2e1db11

Katy Dougherty  
 kdougher@fredhutch.org  
 Security Level: Email, Account Authentication  
 (None)

Signed by:  
  
 7DCF2BEE1F91407...

Sent: 6/12/2026 1:03:40 PM  
 Viewed: 6/12/2026 1:38:37 PM  
 Signed: 6/12/2026 1:57:11 PM

Signature Adoption: Pre-selected Style  
 Using IP Address: 140.107.0.65

**Electronic Record and Signature Disclosure:**  
 Not Offered via Docusign

In Person Signer Events	Signature	Timestamp
Editor Delivery Events	Status	Timestamp
Agent Delivery Events	Status	Timestamp
Intermediary Delivery Events	Status	Timestamp
Certified Delivery Events	Status	Timestamp

<b>Carbon Copy Events</b>	<b>Status</b>	<b>Timestamp</b>
---------------------------	---------------	------------------

<b>Witness Events</b>	<b>Signature</b>	<b>Timestamp</b>
-----------------------	------------------	------------------

<b>Notary Events</b>	<b>Signature</b>	<b>Timestamp</b>
----------------------	------------------	------------------

<b>Envelope Summary Events</b>	<b>Status</b>	<b>Timestamps</b>
--------------------------------	---------------	-------------------

Envelope Sent	Hashed/Encrypted	6/12/2026 1:03:41 PM
Certified Delivered	Security Checked	6/12/2026 1:38:37 PM
Signing Complete	Security Checked	6/12/2026 1:57:11 PM
Completed	Security Checked	6/12/2026 1:57:11 PM

<b>Payment Events</b>	<b>Status</b>	<b>Timestamps</b>
-----------------------	---------------	-------------------

<b>Electronic Record and Signature Disclosure</b>
---

## **ELECTRONIC RECORD AND SIGNATURE DISCLOSURE**

From time to time, Fred Hutch - Non-Part 11 Account (we, us or Company) may be required by law to provide to you certain written notices or disclosures. Described below are the terms and conditions for providing to you such notices and disclosures electronically through the DocuSign system. Please read the information below carefully and thoroughly, and if you can access this information electronically to your satisfaction and agree to this Electronic Record and Signature Disclosure (ERSD), please confirm your agreement by selecting the check-box next to 'I agree to use electronic records and signatures' before clicking 'CONTINUE' within the DocuSign system.

### **Getting paper copies**

At any time, you may request from us a paper copy of any record provided or made available electronically to you by us. You will have the ability to download and print documents we send to you through the DocuSign system during and immediately after the signing session and, if you elect to create a DocuSign account, you may access the documents for a limited period of time (usually 30 days) after such documents are first sent to you. After such time, if you wish for us to send you paper copies of any such documents from our office to you, you will be charged a \$0.00 per-page fee. You may request delivery of such paper copies from us by following the procedure described below.

### **Withdrawing your consent**

If you decide to receive notices and disclosures from us electronically, you may at any time change your mind and tell us that thereafter you want to receive required notices and disclosures only in paper format. How you must inform us of your decision to receive future notices and disclosure in paper format and withdraw your consent to receive notices and disclosures electronically is described below.

### **Consequences of changing your mind**

If you elect to receive required notices and disclosures only in paper format, it will slow the speed at which we can complete certain steps in transactions with you and delivering services to you because we will need first to send the required notices or disclosures to you in paper format, and then wait until we receive back from you your acknowledgment of your receipt of such paper notices or disclosures. Further, you will no longer be able to use the DocuSign system to receive required notices and consents electronically from us or to sign electronically documents from us.

### **All notices and disclosures will be sent to you electronically**

Unless you tell us otherwise in accordance with the procedures described herein, we will provide electronically to you through the DocuSign system all required notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you during the course of our relationship with you. To reduce the chance of you inadvertently not receiving any notice or disclosure, we prefer to provide all of the required notices and disclosures to you by the same method and to the same address that you have given us. Thus, you can receive all the disclosures and notices electronically or in paper format through the paper mail delivery system. If you do not agree with this process, please let us know as described below. Please also see the paragraph immediately above that describes the consequences of your electing not to receive delivery of the notices and disclosures electronically from us.

#### **How to contact Fred Hutch - Non-Part 11 Account:**

You may contact us to let us know of your changes as to how we may contact you electronically, to request paper copies of certain information from us, and to withdraw your prior consent to receive notices and disclosures electronically as follows:

To contact us by email send messages to: [contractsignature@fredhutch.org](mailto:contractsignature@fredhutch.org)

#### **To advise Fred Hutch - Non-Part 11 Account of your new email address**

To let us know of a change in your email address where we should send notices and disclosures electronically to you, you must send an email message to us at [contractsignature@fredhutch.org](mailto:contractsignature@fredhutch.org) and in the body of such request you must state: your previous email address, your new email address. We do not require any other information from you to change your email address.

If you created a DocuSign account, you may update it with your new email address through your account preferences.

#### **To request paper copies from Fred Hutch - Non-Part 11 Account**

To request delivery from us of paper copies of the notices and disclosures previously provided by us to you electronically, you must send us an email to [contractsignature@fredhutch.org](mailto:contractsignature@fredhutch.org) and in the body of such request you must state your email address, full name, mailing address, and telephone number. We will bill you for any fees at that time, if any.

#### **To withdraw your consent with Fred Hutch - Non-Part 11 Account**

To inform us that you no longer wish to receive future notices and disclosures in electronic format you may:

- i. decline to sign a document from within your signing session, and on the subsequent page, select the check-box indicating you wish to withdraw your consent, or you may;
- ii. send us an email to [contractsignature@fredhutch.org](mailto:contractsignature@fredhutch.org) and in the body of such request you must state your email, full name, mailing address, and telephone number. We do not need any other information from you to withdraw consent.. The consequences of your withdrawing consent for online documents will be that transactions may take a longer time to process..

### **Required hardware and software**

The minimum system requirements for using the DocuSign system may change over time. The current system requirements are found here: <https://support.docusign.com/guides/signer-guide-signing-system-requirements>.

### **Acknowledging your access and consent to receive and sign documents electronically**

To confirm to us that you can access this information electronically, which will be similar to other electronic notices and disclosures that we will provide to you, please confirm that you have read this ERSD, and (i) that you are able to print on paper or electronically save this ERSD for your future reference and access; or (ii) that you are able to email this ERSD to an email address where you will be able to print on paper or save it for your future reference and access. Further, if you consent to receiving notices and disclosures exclusively in electronic format as described herein, then select the check-box next to ‘I agree to use electronic records and signatures’ before clicking ‘CONTINUE’ within the DocuSign system.

By selecting the check-box next to ‘I agree to use electronic records and signatures’, you confirm that:

- You can access and read this Electronic Record and Signature Disclosure; and
- You can print on paper this Electronic Record and Signature Disclosure, or save or send this Electronic Record and Disclosure to a location where you can print it, for future reference and access; and
- Until or unless you notify Fred Hutch - Non-Part 11 Account as described above, you consent to receive exclusively through electronic means all notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you by Fred Hutch - Non-Part 11 Account during the course of your relationship with Fred Hutch - Non-Part 11 Account.